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ABSTRACT 
Asmarines, a group of cytotoxic compounds isolated from the marine sponge Raspailia sp. found 
in the Red Sea, has been a target of total synthesis since its discovery in the late 1990s.
1
 At its 
core, Asmarines contain the tricyclic tetrahydrodiazepinopurine (THDAP) ring system A which 
has presented various synthetical challenges.  
An initial route to THDAPs starting from a pyrimidine derivative was attempted. This method 
was found to be unsuitable for the synthesis THDAPs (Section 2.1) 
One other possible synthetic route was also attempted starting from commercially available 
adenine, in which a major challenge is the selective alkylation of the N-7 position over the 
preferred N-9 position (Section 2.2). In this Project, a method for constructing N-7 substituted 
adenine is presented. The new synthetic route did not go according to plan, but did produce an 
interesting hemiaminal ether, which can possibly be a useful intermediate in the total synthesis of 
asmarines. 
 
                       
During the project, a novel methodology for the reduction of electron-poor Boc-protected purines 
to the corresponding 7,8-dihydropurines was discovered. These are important intermediates in the 
synthesis of potentially bioactive 7-substituted purines.
2,3
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ABBREVIATIONS 
Aq. Aqueous 
Bn Benzyl 
Boc tert-Butoxycarbonyl  
br broad (NMR) 
C Carbon 
Calc. Calculated 
COSY Correlation spectroscopy 
Δ heating 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene  
DCM Dichloromethane 
DMAP 4-Dimethylaminopyridine  
DMF Dimethylformamide  
DMSO Dimethyl sulfoxide 
EI Electron impact 
Eq. Equivalents  
Et al. et alii 
EtOAc Ethyl acetate  
GI50 growth inhibition that inhibits 50 % 
h hour(s) 
HMBC Heteronuclear multiple-bond correlation  
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HRMS High resolution mass spectrometry 
HSQC Heteronuclear single-quantum coherence  
Hz hertz 
IC50 Inhibitory concentration that inhibits 50 % 
J coupling constant (NMR) 
LiHMDS Lithium hexamethyldisilazide 
M multiplet (NMR) 
M
+
 molecular ion peak (MS) 
Me Methyl  
MeOH Methanol 
MHz megahertz 
MS Mass spectrometry 
M.p. Melting point 
m/z mass to charge ratio 
n.r. no reaction  
NMR Nuclear magnetic resonance  
r. t. Room temperature  
s Singlet (NMR)  
sat. saturated 
Temp. temperature 
Tert tertiary 
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d dublet (NMR) 
t Triplet (NMR)  
TFA Triflouroacetic acid  
THDAP tetrahydro-[1,4]diazepino[1,2,3-gh]purine 
THF Tetrahydrofuran  
TLC Thin layer chromatography 
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1. INTRODUCTION 
This section will provide a brief introduction to natural products and their current role in 
pharmaceuticals. Existing information available on asmarines will be summarized, such as their 
origin and biological activity as well as the synthetic endeavors that have been carried out in this 
area thus far. 
1.1 NATURAL PRODUCTS 
Nature is a vast source of biologically active compounds of great potential benefit.
4
 They are 
called natural products and encompass all molecules that are produced by a living organism. The 
percentage of drugs approved by the FDA between 1981 and 2006 that was either a natural 
product or inspired by a natural product was roughly 52 %.
4
 Only about 30 % were completely 
synthetic in origin. Of the 155 small molecule anti-cancer drugs approved, 47 % were natural 
products or natural product derivatives. These numbers reflect nature’s important role as an 
inspiration for new pharmaceuticals.  
A vast majority of nature’s bioactive compounds are secondary metabolites. These are molecules 
that do not directly play a role in the development and reproduction of an organism, but provides 
some other evolutionary advantage to the organism, like fighting off microbes or repelling 
herbivores. These metabolites are important sources of new drugs as they already elicit powerful 
biological activity needed for these compounds to benefit the organism. 
1.1.1 Traditional sources of natural products  
Higher plants have been an important source of natural products since the isolation of morphine 
(Figure 1) from the poppy papaver somniferum in 1804.
5
 Examples of important compounds that 
has been isolated from the plant kingdom include digoxin, quinine, quinidine, vincristine , 
vinblastine and atropine.
6
 Taxol, isolated from the bark of the Pacific yew tree Taxus brevifolia, 
is a potent anticancer drug that became a huge commercial success for the treatment of ovarian-, 
breast- and some lung-cancers in the late 1990s.
7
 In 2000, about one in four drugs prescribed 
worldwide originated from plants.
6
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Figure 1. The structure of morphine, taxol and quinidine; natural products used as drugs. 
The discovery of penicillin in 1929 spawned an era of exploration of microorganisms as a source 
of drugs.
5
 Massive screening efforts were carried out after the Second World War looking for 
new antibiotics. Some of the most important drugs resulting from this screening include 
erythromycin, cephalosporin C and daunorubicin. Daunorubicin (Figure 2) served as a starting 
point for the synthesis of many other related compounds called anthracyclines including the 
important doxorubicin used in cancer chemotherapy. These compounds are some of the most 
effective antineoplastic compounds discovered with the widest spectrum of activity in human 
cancers.
8
 
Animals also produce compounds with attractive pharmacological properties.
9-11
 For instance, it 
was estimated that approximately 4 % of 800 evaluated arthropod extracts in the 1970s showed 
some degree of cytotoxicity.
12
 Insects also provide a host of various chemical substances of 
interesting biological activity. Many of these substances are present in insects because of their 
extensive use of chemicals as a defense mechanism.
10
 Venoms and toxin from snakes, spiders 
and frogs also contain potential lead compounds for novel therapeutics.
13,14
 Epibatidine, a 
poisonous alkaloid present on the skin of certain species of poison dart frogs, was shown to 
possess analgesic properties 200 times more potent than morphine.
15
 Although it is too poisonous 
to be used as a drug, it serves as a lead compound for the development of less toxic derivatives.
16
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Figure 2. The structure of Epibatidine; penicillin G and Daunorubicin. 
 
 
 
 
1.1.2 Marine sources of natural products 
In recent years, there has been an upsurge in drug discovery of natural products and lead 
compounds from marine sources.
17
 The most common such sources are the marine invertebrates 
which comprise around 60 % of all marine animal diversity.
18
 These organisms are often soft-
bodied, sedentary life-forms and hence often rely on chemical defense for survival. Since an 
aqueous environment quickly dilutes any chemical substances excreted by an organism, these 
molecules must possess potent biological activity in order to achieve its intended effect.
19
 This 
creates an environment that is rich in potent bioactive compounds and marine organisms are thus 
attractive targets for the bioprospecting of potential drugs.
20,21
  
Some of the earliest examples of natural products derived from marine sources are 
spongothymidine and spongouridine (Figure 3) isolated from the sea sponge Cryptotethia 
crypta.
22
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Figure 3. Structure of spongothymidine, spongouridine, vidarabine and cytarabine; compounds possessing antiviral 
activity. 
These compounds were the inspiration for drugs such as vidarabine and cytarabine in clinical use 
today.
23
 Vidarabine was initially planned to be an anticancer drug but was in the process 
discovered to possess significant antiviral activity.
24
 Today, it is typically used in the treatment of 
diseases caused by herpes, pox- and rhabdoviruses.  
The occurrence of cytotoxic activity in extracts of marine organisms far exceeds that of terrestrial 
samples.
20
 Despite the abundance of potent, biologically active compounds found in marine 
ecosystems, very few clinically approved drugs of marine origin is found on the market. There 
are several reasons for this,
5
 but perhaps the biggest reason is the lack of biomass available from 
wildstocks. The limited supply of material needed for drug development, severely hinders 
advancement in this area of drug discovery.
20
  
Bioprospecting of marine natural products is still a relatively new endeavor, but has already 
produced thousands of new compounds.
18
 Due to the ocean’s huge biodiversity, the number of 
discovered marine natural products as candidates for novel pharmaceutical agents is only 
expected to rise.  
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1.2 ASMARINES 
Asmarines are a class marine alkaloids first reported isolated in 1998 from the sea sponge 
Raspailia.
25
 Initial screening revealed they possess significant cytotoxicity against various types 
of cancer cells, including some important human cancer cell lines. The discovery of these 
compounds and their close similarity to agelasines and agelasimines, another set of marine 
alkaloids previously studied in our group shown to possess antimicrobial and antineoplastic 
activities,
26-31
 has prompted research to try to synthesize these molecules. So far no total 
synthesis of any of the asmarine analogs has been reported in the literature. 
1.2.1 Isolation, structure and biological activity 
The discovery of the first asmarines was a result of a collaboration between researchers at the 
School of Chemistry with the Tel-Aviv University in Israel and the Oceanographic Research 
Institute (ORI) in the Republic of South Africa.
25
 A sample of the marine sponge Raspailia 
(Demospongiae, Poecilosclerida, Microcionina, Raspailiidae) found in the Red Sea off the coast 
of Eritrea was collected and frozen on site. Chemical analysis of the freeze-dried sample, 
revealed three novel structurally related metabolites, named asmarine A – C. The same group 
reported three new asmarines (D – F) in 2000 and five more (G – K) in 2004 for a total of eleven 
compounds (Figure X).
32-34
 
 
Figure 4. The structures of all asmarines currently known.  
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Asmarines G and H was isolated from sponges near Shimoni in the Wasini Channel of southern 
Kenya while asmarines I, J and K appear in sponges in the waters near the Nosy Be Islands of 
Madagascar. Asmarines A and F are the only asmarines that have appeared in all of the three 
areas investigated. 
Asmarines consist of a fused diterpene-heterocyclic structure. The diterpene-portion of the 
molecule resembles naturally occurring chelodane
35
 and contains five stereocenters. Only one of 
the stereocenters (marked in Figure 4) has shown variation among the asmarine analogs. The 
heterocyclic part of the molecule is based on adenine. Conjugation of these two moieties is 
believed to be the biosynthetic origin of asmarines.
1
 
Initial screening of asmarine A and B has revealed cytotoxicity against cell cultures of P-388 
murine leukemia, A-549 human lung carcinoma, HT-29 human colon carcinoma and MEL-28 
human melanoma.
25
 The results of these studies are listed in Table 1.  
Table 1. Anti-tumor activity of Asmarine A and B listed as IC50-values in µM. 
 P-388 A-549 HT-29 MEL-28 
Asmarine A 1.18 1.18 1.18 1.18 
Asmarine B 0.24 0.12 0.12 0.24 
 
Asmarines A and B, together with several synthetic analogs, was later tested for cytotoxic 
activity against DU-145 prostate, IGROV-ET ovarian, SK-MEL-28 melanoma, A549 NSCL, 
PANC1 pancreas, HT29 colon and LOVO colon cancer cell lines (Table 2).
36
 
 
Table 2. GI50-values of asmarine A and B against various cancer cell lines in µg/mL. 
 Prostate 
DU-145 
Ovarian 
IGROV-ET 
Melanoma 
SK-MEL-
28 
NSCL 
A549 
Pancreas 
PANC1 
      Colon 
HT29   LOVO 
Asmarine A 2.7 0.7 2.7 4.1 1.1 0.4 1.0 
Asmarine B - - 0.5 0.4 - 0.04 - 
 
16 
 
All synthetic analogs were found to be at least one order of magnitude less active than asmarine 
B. The importance of the hydroxyl-group in asmarine A and B for biological activity was also 
established; asmarine H shows no cytotoxic activity.  
 
1.2.2 Related compounds 
Two other subclasses of bioactive metabolites from marine sponges (Agelas sp., Raspailia sp.) 
are known: Agelasines and agelasimines. Far more is known about the biological activity of these 
compounds than for the related asmarines. Several synthetic analogs have been prepared and 
many of are even more potent than the naturally occurring compounds. Biological activities range 
from antibacterial,
26,27,29
 antifungal,
3,26,27,31
 antiprotozoal,
31,37,38
 antineoplastic activity
3,28,31,39
 to 
biofilm inhibition and antifouling properties.
40-42
   
 
Figure 5. Structure of agelasine A and agelasimine A. 
The close resemblance of agelasines and agelasimines to asmarines becomes evident from Figure 
5. A key difference is the lack of the seven-membered ring seen in asmarines. Agelasines also 
contain an N-quaternary functionality.  
 
1.3 PREVIOUS ATTEMPTS ON THE SYNTHESIS OF 
DIAZEPINOPURINE RING-SYSTEMS 
So far, no asmarine has been prepared by total synthesis. Most of the chemistry reported on 
asmarine total synthesis has been on the heterocyclic-portion of the molecule. This 5-, 6-, 7-
17 
 
membered tricyclic structure is referred to as THDAP (tetrahydro-[1,4]diazepino[1,2,3-
gh]purine) (Figure 6).  
 
Figure 6. Numbering system for purine, diazepine and the THDAP core structure. 
The main difficulty in synthesizing the THDAP ring-system lies in the construction of the seven-
membered, diazepine-ring. The synthesis of THDAP and its derivatives can be divided into five 
strategies (a-e) based on which bond is formed in the ring-closing step of the diazepine ring 
(Figure 7). 
 
Figure 7. Bonds a-e refer to the five different strategies used to categorize the major synthetic routes to THDAP 
molecules. 
This section will give an overview of previous attempts at constructing the THDAP ring-system.  
1.3.1 The first appearances of THDAPs in literature 
The first example of the heterotricyclic diazepinopurine ring-system appearing in literature, was 
in 1977 by Glushkov et al.
43
 While working on xanthine derivatives in the search for new 
spasmolytic drugs, they managed to ring-close an N-7 alkylated 3-methylxanthine by treatment in 
neat phosphoryl chloride (Scheme 1). 
18 
 
 
Scheme 1. Ring-closing of an N-7 alkylated  3-methylxanthine derivative using phosphoryl chloride. 
*
Individual 
yields were not reported. 
In 1985, Brahme and Smith reported synthesizing a THDAP from adenine by addition of acrylic 
anhydride in dry DMSO (Scheme 2).
44
 
 
Scheme 2. Synthesis of 7,8-dihydro-[1,4]diazepino[1,2,3-gh]purin-9(10H)-one.
44
 
1.3.2 Synthetic studies toward asmarines 
The first synthesis of a THDAP system directed towards the total synthesis of asmarines, was 
performed by Kashman et al. (Scheme 3).
45
   
 
Scheme 3. Synthesis of 3-benzyl THDAP as an HCl salt. 
*
 No yields reported. 
In this case, the bulky benzyl group at N-3 steers further alkylations to take place at N-7 rather 
than the now sterically crowded N-9 position, thus making it possible to form the desired THDAP 
system.  
19 
 
The same group also proposed and tested two possible cyclizations to form the 10-hydroxy-
THDAP system seen in most asmarines. The two routes involve either going through synthon S1, 
cyclizing on N-7 (strategy e) or through synthon S2 cyclizing on N-6 (strategy b) (Figure 8).  
 
Figure 8. Two proposed synthons for the synthesis of 10-hydroxy-THDAP.
45
 
The group’s attempt at cyclizing through an S1-type molecule failed as cyclization took place on 
N-1 rather than on N-7 (Scheme 4). 
 
Scheme 4. Cyclization on N-1. 
*
No yields reported. 
On the other hand, ring-closure of an S2-type molecule has only one possible site of cyclization, 
namely N-6. Indeed this reaction produced the intended THDAP ring-system (Scheme 5). 
 
Scheme 5. Cyclization producing a possible 10-hydroxy-THDAP precursor using strategy b. 
*
 No yields reported. 
However, a method to deprotect the di-benzylated THDAP system to produce the more 
interesting 10-hydroxy-THDAP was revealed to be problematic.
46
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Ohba et al. has reported methods to synthesize 10-hydroxy-THDAP, 4-methyl-5-oxo-THDAP 
and 10-methoxy-4-methyl-5-oxo-THDAP, the three major structural motifs for the tricyclic 
skeleton of asmarines.
47
 
The synthesis of 10-hydroxy-THDAP was achieved by cyclization of a pyrimidine derivative 
(Scheme 6).  
 
Scheme 6. First successful synthesis of 10-hydroxy-THDAP.
47
 
The reasoning behind the use of this route is that direct alkylation of 6-chloropurine by alkyl 
halides or under Mitsunobu conditions is reported to occur preferentially on N-9.
48-57
 By starting 
with 4-amino-6-chloro-5-formamidopyrimidine, the desired nitrogen can be alkylated under basic 
conditions and then cyclized to form the purine ring.  
Strategy a has only been used to synthesize THDAP-systems unsubstituted in the diazepine-ring. 
It is, however, also the only method to have produced the 4-methyl-5-oxo-THDAP motif seen in 
asmarine C-F (Scheme 7). 
 
Scheme 7. Ring-closing by nucleophilic aromatic substitution. 
Strategy b is so far the only strategy successfully used to form C-9-substituted THDAPs.
46,58
 
Starting from 6-chloropurine, the N-9 position is protected and a nucleophilic aromatic 
21 
 
substitution introduces the hydroxylated nitrogen (Scheme 8). Subsequent alkylation at the N-7 
position carries the desired substituents and the right functionality to allow ring-closing under 
Mitsunobu conditions. 
 
Scheme 8. Ring-closing using strategy b to afford C-9 substituted THDAPs.
46
 
Limitations to this synthesis are low yields in the protection and deprotection step and the lack of 
stereochemical control in the ring-closing step.  
Strategy d has previously been used in our group to synthesize THDAP by ring-closing 
metathesis (RCM).
59
 Stereochemistry is not an issue in this route. Jähne et al. showed that 
selective N-7-allylation of 6-chloropurine can be achieved by using a Co-complex.
60
 Using this 
reaction circumvented the need for N-9-protection. After introducing an allylamino-group in the 
6-position, the double bond could selectively be rearranged to N-allyl-7-(1-propen-1-yl) purin-6-
amine under basic conditions to allow seven-membered ring-formation after the RCM reaction 
(Scheme 9). 
22 
 
 
Scheme 9. Synthesis of THDAP by ring-closing metathesis. 
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1.4 Chemistry 
 
This section will cover some aspects of the chemistry used in the master’s project. 
 
1.4.1 Nucelophilic aromatic substitution on purines and pyrimidines 
The electron-poor nature of purines and pyrimidines means they are activated towards 
nucleophilic aromatic substitution reactions (SNAr). Halogens in the 2-, 4- and 6-position of 
pyrimidines and the 2- and 6-position of purines provide excellent substrates for the introduction 
of a diverse number of substituents and are therefore common starting materials and 
intermediates in organic synthesis. Activation in these positions is a result of both inductive and 
mesomeric withdrawal of electrons by adjacent nitrogens as well as the inductive withdrawal of 
electrons by the halogen itself.
61
 Polyhalogenated purines and pyrimidines will in most cases 
preferentially undergo substitution at the 4- and 6-position, although mixtures are common. The 
rate of reaction is largely determined by the electronegativity of the halogen. An increase in 
electronegativity will more strongly polarize the carbon-halogen-bond leaving carbon with a 
greater partial positive charge and thus more prone to nucleophilic attack. The leaving group-
ability of the halogen has little to no impact on the reaction rate as the initial attack forming the 
Meisenheimer complex and breaking aromaticity is the rate-determining step (Scheme X). The 
aromaticity is restored in the second step when the leaving group is eliminated and is thus a fast 
reaction. This means that the halogen’s order of reactivity for nucleophilic aromatic substitution 
is: F>Cl>Br>I, which is the opposite of regular Sn1 and Sn2-type reactions.
62
  
 
Scheme 10. Reaction mechanism of nucleophilic aromatic substitution on pyrimidine. 
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The presence of other substituents can greatly affect the propensity for nucleophilic aromatic 
substitution. As a general rule, electron-withdrawing groups will increase reaction rates, while 
electron-donating groups will decrease reaction rates. The presence of electron-withdrawing 
groups can inductively and mesomerically help stabilize the negative charge introduced by the 
nucleophile to lower the activation barrier of the rate-determining step. On the other hand, an 
electron-donating group will increase the aromatic stabilization of the reactant molecule and 
destabilize the negative charge increasing the activation barrier. 
1.4.2 The tert-butoxycarbonyl (Boc) group – the role of DMAP 
The tert-butoxycarbonyl (Boc) group is one of the most frequently used protecting group for 
amines in organic synthesis.
63
 Conversion of amines to the corresponding tert-butyl carbamate 
drastically alters the reactivity of the amine allowing for other reactions to take place that would 
otherwise affect the amino-group. Boc-groups are usually stable under basic conditions, resistant 
to catalytic hydrogenolysis and inert toward most nucleophiles. It cleaves under moderate to 
strong acidic conditions, making it an ideal orthogonal partner to benzyl esters and other 
carbamates commonly used in peptide synthesis.
64
  
Boc-protection of amines is generally achieved by adding di-tert-butyl dicarbonate to the free 
amine in a suitable solvent with or without added bases such as triethylamine or 
diisopropylethylamine (DIPEA).
63
 The addition of catalytic amounts of 4-dimethylaminopyridine 
(DMAP) will in many cases decrease reactions times and even allow for protection of groups that 
otherwise does not react. Sometimes addition of DMAP completely changes the outcome of the 
reaction.
65
  
DMAP acts as a nucleophilic catalyst in acylation reactions.
66,67
 The basis for the catalytic 
properties lies in its ability to form 1-acyl pyridinium salts (Scheme 11). These salts are often 
more reactive than the parent anhydride and thus facilitate acylation. 
25 
 
 
Scheme 11. Catalytic action of DMAP with anhydrides to produce reactive 1-acyl pyridinium salts. 
Boc-protection of purine-derivatives will in most cases produce the N-9 protected isomer.
68-70
 It 
has been suggested that, in the presence of DMAP, these reactions are reversible and will initially 
produce mixtures of N-7 and N-9 protected isomers that over time resolves into the more 
thermodynamically stable product.
71
 This would indicate the presence of an intermediate salt x 
(Scheme 12). 
 
Scheme 12. Action of DMAP on Boc-protected purines.
71
 
Deprotection of Boc-groups are usually achieved in neat trifluoroacetic acid (TFA) or mixtures of 
TFA in DCM.
63
 Other common protocols are HCl in methanol or dioxane. The mechanism of 
deprotection is depicted in Scheme 13.
62
 
26 
 
 
Scheme 13. Mechanism of Boc-deprotection.
62
 
As shown in Scheme 13, N-7 and N-9 Boc-protected purines are prone to deprotection under non-
acidic conditions. Even simple heating in nucleophilic solvents like methanol will deprotect Boc-
protected adenine in the N-9 position.
68
 This effect can be attributed to the resonance-stabilized 
imidazolide ion formed in such nucleophilic deprotections.  
 
1.4.3 Reductions using borane and sodium borohydride 
Borane complexes like BH3•THF and BH3•DMS are reducing agents commonly used in 
hydroborations.
62
 The reagent adds across double bonds in a concerted step most often producing 
the anti-Markovnikov product (Scheme X). The anti-Markovnikov product is formed because of 
steric interactions between the carbon substituents and boron. 
 
Scheme 14. Mechanism of borane addition over double bond.  
The hydroborated product can serve as a useful intermediate for following chemical 
transformations. The product can be treated with aqueous acidic solutions to afford the reduced, 
non-functionalized product or, more commonly, treated with hydrogen peroxide to afford the 
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alcohol. The latter, two-step hydroboration/oxidation reaction is a powerful synthetic tool used to 
make alcohols from alkenes by cis-addition of water.
62
  
Limited information exists regarding the interaction of purines and boranes. Hirota et al. reduced 
inosine-derivatives to the corresponding 2,3-dihydroinosine.
72
 The proposed mechanism involves 
complexation of borane to N-3 of the purine followed by hydride-delivery to the adjacent C-2. 
The proposed mechanism for the borane-reduction performed in this project is outlined in 
Scheme 15. 
 
Scheme 15. Proposed mechanism of the borane-reduction used in this project. 
Sodium borohydride is a widely used reducing agent in organic chemistry.
73
 It is often chosen 
over other reducing agents for its safety and ease of handling. A major drawback is its relatively 
weak reducing strength, only capable of reducing the most reactive functional groups like imines, 
aldehydes, ketones and acyl chlorides.
74
  
Sodium borohydride is a source of nucleophilic hydride-ions, the reactivity of which can be 
enhanced by the addition of methanol.
75,76
 When alcohols react with sodium borohydride, various 
alkoxy hydroborates are produced. These intermediate species possess greater reducing 
capabilities than the original borohydride due to the electron-donating ability of the alkoxy group 
(Scheme X). The reaction will eventually lead to alkyl borate, quenching the reductive 
hydroborate intermediates.  
 
Scheme 16. Reaction between simple alcohols and the borohydride ion. The electron-donating ability of the alkoxy-
groups increases the nucleophilicity of the hydride-ions. 
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1.4.4 Michael addition 
Michael addition allows for the introduction of alkyl chains with an electron-withdrawing group 
three carbons away from the nucleophile (Scheme 17). Typically the functional group is a 
carbonyl, but also other groups such as nitriles and nitro-groups are used. Although the traditional 
Michael addition is a conjugate addition of an α,β-unsaturated carbonyl compound to the enolate 
of a ketone or aldehyde, any nucleophile undergoing 1,4-addition will be referred to as a 
Michael-type reaction in this thesis.  
 
Scheme 17. Mechanism of conjugate addition. 
Conjugate addition is favorable with moderate to soft nucleophiles like amines, thiols and 
malonates.
62
 This makes purines excellent substrates for Michael-type additions.
77-80
  
 
 
 
 
 
 
 
 
S  
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2. SYNTHESIS 
This section will cover all chemistry done in the Master’s project. 
 
2.1 Synthesis of THDAPs using strategy e 
The proposed synthetic route is outlined in Scheme 18. This route was selected in order to test 
whether or not a pyrimidine-derivative would act differently than its purine analog in the 
cyclization step previously reported to occur on N-1.
45
 
 
Scheme 18. Original synthetic route. 
 
2.1.1 Synthesis of 3-((5-amino-6-chloropyrimidin-4-yl)amino)propan-1-ol (2) 
5-amino-4,6-dichloropyrimidine 1 was reacted with 3-amino-1-propanol through a nucleophilic 
aromatic substitution to form 3-((5-amino-6-chloropyrimidin-4-yl)amino)propan-1-ol 2 (Scheme 
19). The reaction is reported in the literature. 
81,82
  
 
Scheme 19. Reagents and conditions: 3-Aminopropan-1-ol, 1,4-dioxane, 90 °C, 20 h. 
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Using an excess of 3-amino-1-propanol, the reaction shows complete conversion after about 20 
hours at 90 °C. 
1
H NMR- and TLC-analysis reveal the reaction produces a single product 2. 
Yields usually lie between 50 – 65 % when purifying by recrystallization, somewhat less than the 
reported literature values of 80 – 81 %. Recrystallization from water, as reported in the 
literature,
81,82
 affords the monohydrate not suitable for further chemistry without extensive 
drying. Purifying the product using flash column chromatography instead of recrystallization 
increases the yield to 92 % and avoids the need to remove water from the product. 
 
2.1.2 8-chloro-3,4-dihydro-2H-pyrimido[1,6-a]pyrimidin-9-amine 
hydrochloride (7) 
Analogous to the scheme used by Kashman et al.
45
, compound 2 was treated with thionyl 
chloride. Although a likely intermediate, compound 3 was not isolated as ring-closure occurred 
spontaneously. However, the intended product 4 was not observed. Instead, ring-closure took 
place on N-1 affording compound 7 as the hydrochloride salt (Scheme 20). 
 
Scheme 20. Reagents and conditions: SOCl2, THF, 1 hour at 0 °C then 1.5 hours at r.t. 
Monitoring the reaction by TLC, full conversion is seen after 2 hours producing two main spots, 
one of which resides on the baseline eluting with DCM:MeOH (94:6). NMR analysis of the crude 
reaction mixture shows two products in a 2:1 ratio with compound 7 being the major. Upon 
standing, the minor compound gradually disappears over the course of a few days at room 
temperature in the NMR tube, leaving compound 7 as the sole product. MS analysis shows a peak 
corresponding to compound 3 (Scheme 21), which is the proposed reactive molecule producing 
compound 2 over time. Stirring the evaporated reaction mixture in THF at room temperature for 
three days produces product 7 in quantitative yields. 
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Scheme 21. Conditions: THF, r.t., 3 days. 
When triethylamine is added to keep the pH level of the reaction solution more stable, no traces 
of compound 3 can be spotted either by MS, TLC or 
1
H NMR analysis. This is likely due to a 
lower proportion of reactant molecules in a protonated state and thus more likely to act as 
nucleophiles (Figure 9). 
 
Figure 9. Protonation decreases the propensity of nucleophilic attack. 
 
2.1.3 Substrate modification  
A similar reaction pathway was attempted, substituting 3-aminopropan-1-ol with 3-
(methylamino)propan-1-ol to test the effect of the methyl group on the reaction outcome. Since 
ring-closure at the N-1 position in this case would produce a permanently charged product, it was 
anticipated that this would alter the dynamics of the reaction in such a way as to produce the 
neutral seven-membered ring-closed product instead (Scheme 22). 
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Scheme 22. Possible reaction directions after introduction of methyl-substituent. 
 
 
2.1.4 Synthesis of 3-((5-amino-6-chloropyrimidin-4-yl)(methyl)amino)propan-
1-ol (10)  
3-((5-Amino-6-chloropyrimidin-4-yl)(methyl)amino)propan-1-ol (10) was prepared in the same 
manner as compound 2 (Scheme 23).  
 
 
Scheme 23. Reagents and conditions:  3-Methylaminopropan-1-ol, 1,4-dioxane, 20 h., reflux.  
Complete conversion is observed after 20 h by TLC-analysis, showing one big product spot along 
with other minor spots of higher polarity. The yield is excellent (96 %).  
 
2.1.5 Synthesis of 9-amino-8-chloro-1-methyl-
1,2,3,4-tetrahydropyrimido[1,6-a]pyrimidinium chloride (11) 
Treating compound 10 with thionyl chloride, analogous to the reaction in Scheme 20, did not 
produce the desired seven-membered product 9. Also this reaction afforded the N-1 ring-closed 
compound (Scheme 24). 
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Scheme 24. Reagents and conditions: SOCl2, THF, 90 min. at 0 °C then 1 h at r.t.  
Yet again the crude NMR spectra showed a major product and a minor one (~14:1) disappearing 
over time. This time, the spectrum didn’t clear up quite as cleanly as the reaction in scheme 21 
upon standing. Purification of the salt was difficult. 
 
2.1.6 Attempted ring-closure of 3-((5-amino-6-chloropyrimidin-4-
yl)amino)propan-1-ol (2) under Mitsunobu conditions 
After the lack of success following the original scheme, where cyclization is brought about by a 
two-step process of leaving group transformation and subsequent alkylation, an attempt at uniting 
the two by virtue of the Mitsunobu reaction was made.  
The Mitsunobu reaction has gained widespread popularity as an effective way to displace 
hydroxyl groups with a variety of nucleophiles.
83-85
 The proposed mechanism is outlined in 
Scheme 25.  
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Scheme 25. Mechanism of the Mitsunobu reation.
83
 
Compound 2 failed to produce any product under two common variations to the conditions of the 
Mitsunobu reaction (Scheme 26).  
 
Scheme 26. Reagents and conditions: a – A solution of 2a and triphenylphosphine (1.1 eq.) in THF was added 
slowly to a solution of DIAD (1.1 eq.) in THF at 0 °C over 35 min., warmed to r.t. and stirred for 3 h. b – A solution 
of 2a in THF was added slowly to a pre-made solution of DIAD (1.1 eq.) and triphenylphosphine (1.6 eq.) in THF at 
0 °C over 30 min., heated to reflux and stirred for 18 h. 
In both instances (a and b of Scheme 26), only starting material could be observed by NMR 
analysis of the crude reaction mixture. An explanation for this lack of reactivity may be that the 
pKa of the nucleophilic primary aryl nitrogen is not sufficiently low to allow deprotonation by the 
formed betaine (step 2, Scheme 25) thus preventing any further reaction. This limitation is well-
known in the literature.
86,87
     
 
35 
 
2.1.7 Attempted oxidations of 3-((5-amino-6-chloropyrimidin-4-
yl)amino)propan-1-ol (2) 
A few attempts at oxidizing compound 2 to the corresponding aldehyde 9 were made. The 
objective was to ring-close by reductive amination (Scheme 27).  
 
Scheme 27. Ring-closure by reductive amination. 
Three oxidation strategies were tried: Swern oxidation, Dess-Martin oxidation and oxidation 
using pyridinium chlorochromate (Scheme 28). 
 
Scheme 28. Reagents and conditions: a – DMSO, oxalyl chloride, triethylamine, THF, 1.5 h. at -78 °C then 24 h. at 
r.t. b – Dess-Martin Periodinane, THF, 30 min. at 0 °C then 24 h. at r.t. c – Pyridinium chlorochromate, DCM/THF, 
4 h. at r.t.   
The Swern oxidation produced an array of unidentified products and no amount of the desired 
aldehyde 12 was observable in the crude reaction mixture by either NMR or MSanalysis. Other 
possible products such as the ring-closed imine analog of compound 4 or the ring-closed enamine 
analog of compound 7 were not found either. Common side-products of Swern oxidations are 
methylthiomethyl ethers resulting from a pummerer-type rearrangement of the ylide.
88,89
 No such 
side-products were observed. Oxidation by Dess-Martin periodinane failed to produce any of the 
desired aldehyde 12. Immediately after addition of the periodinane, a sudden change of color to a 
deep red was observed. TLC-analysis of the reaction showed a large array of highly polar 
compounds on or close to the baseline eluting with DCM in MeOH (9:1). Due to the large 
number of inseparable products, identification was difficult. Oxidation using pyridinium 
chlorochromate also produced a vast number of highly polar compounds difficult to analyze 
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2.2 Synthesis of THDAPs using Strategy b 
A different approach to the ring-closure of the diazepine ring was conceived starting from 
commercially available adenine (Scheme 30). Based on strategy b (Figure 7), the new synthetic 
route would ring-close by intramolecular imine-formation. The imine-functionality allows for 
nucleophilic addition on C-9 forming substituted 9-methyl-THDAPs as found in the asmarines. 
Having the C-9 carbon in the +II oxidation state not only allows for nucleophilic addition, but 
also means that the alkyl-chain can be introduced via a Michael-type addition on N-7.  
 
Scheme 29. Retrosynthetic analysis of a strategy b-type synthetic route. 
Adenine itself does not selectively produce N-7 alkylated products under Michael conditions as 
the N-9 isomers are favored.
44,90
 This can be mitigated through the use of protecting groups. In 
order to retain a neutral N-9 protected, N-7 alkylated compound, a reduction/oxidation is required 
after protection/deprotection. This allows for easier purification of products as well as milder 
conditions and possibly improved selectivity during Michael addition due to the increased 
nucleophilicity of the N-7 nitrogen. The new synthetic route is outlined in Scheme 31. 
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Scheme 30. Synthetic route based on strategy b. 
The first step can be achieved following a literature procedure.
68
 The reduction, Michael addition 
and subsequent deprotection/oxidation are based on procedures by Dvořák et al. used on similar 
substrates.
69
  
2.2.1 Synthesis of tritert-butyl 9,10,10-adenineetricarboxylate (14a) 
Tritert-butyl 9,10,10-adenineetricarboxylate 14a was made by treating adenine 13 with di-tert-
butyl dicarbonate in THF together with catalytic amounts of 4-dimethylaminopyridine (DMAP) 
(Scheme 32). 
 
Scheme 31. Reagents and conditions: Di-tert-butyl dicarbonate, DMAP, THF, 22 h. at r.t.  
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The reaction was performed following the procedure reported by Dey and Garner.
68
 The reaction 
time was increased from 8 to 22 hours as a second spot could be observed below the product-spot 
on TLC. The reaction was stopped after 22 hours at room temperature when the spot had reduced 
significantly in intensity. The yields (91 %) were near identical to the reported value (90 %). 
Additionally, 8 % of the N-7 substituted isomer 14b was isolated. Formation of the N-7 isomer 
was not reported in the article by Dey and Garner, but is mentioned in an article by Ikonen and 
coworkers,
91
 although not isolated by chromatographic means.   
 
2.2.2 Synthesis of tert-butyl 6-(ditert-butoxycarbonylamino)-8,9-
dihydropurine-9-carboxylate (15) 
Compound 14a was further reacted with a 1 molar borane tetrahydrofuran complex solution in 
THF reducing it to tert-butyl 6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-carboxylate 15 
(Scheme 33). 
 
 
Scheme 32. Reagents and conditions: BH3•THF complex, THF, 2 h. at -78 °C then 18 h. at r.t.    
 
The reaction was done using a modified procedure from Dvořák et al.69 Yields are moderately 
high (78 %). 
1
H NMR analysis of the crude reaction mixture indicates that the main impurity is 
starting material 14a. Increasing the amount of reducing agent (from 1.4 eq. to 2.5 eq.) or the 
reaction time does not change the outcome. TLC analysis of the reaction mixture shows three 
large spots, two of which matches the product and starting material. Spotting the TLC-plate and 
letting it sit in open atmosphere for 15 min. before elution eliminates the third spot. The third spot 
is likely to be some sort of borane-adduct either of the starting material or the product. Leaving 
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the compound in solution at room temperature with access to air will slowly oxidize it back to 
compound 14a (Figure 10).  
 
Figure 10. Figure showing the oxidation of compound 15 over 2 days. 
 
 
 
2.2.3 Synthesis of tert-butyl 6-(ditert-butoxycarbonylamino)-7-(3-oxobutyl)-
8,9-dihydropurine-9-carboxylate (16) and tert-butyl 7-(2-cyanoethyl)-6-
(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-carboxylate (43) 
 
In addition to substrate 16 needed in the synthetic scheme, compound 43 was synthesized under 
similar conditions as a proof-of-concept.  
Michael addition of 15 with but-3-en-2-one or acrylonitrile in acetonitrile produced the N-7 
substituted tris boc-protected adenine 16 or 43 (Scheme 34). 
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Scheme 33. Reagents and conditions: a – (X = COCH3), But-3-en-2-one, DBU, MeCN, 5 h at r.t. b – (X = CN), 
Acrylonitrile, DBU, MeCN, 5 hours at r.t. 
These reaction conditions are also based on the procedure reported by Dvořák et al.69 and in the 
case of compound 16, modified by Urs Fabian Fritze.
92
 Fritze found that slow addition of diluted 
but-3-en-2-one to a solution of 15 in acetonitrile together with 1.1 eq. of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) was needed to obtain satisfactory yields of compound 16. 
Moderately high yields of compound 16 (78 %) were obtained in this project. Unreacted starting 
material accounts for 7 mol% by 
1
H NMR analysis of the crude reaction mixture with no other 
impurities present in sufficient amount. No further attempts to increase the yield were made.  
For compound 43, it was found that slow addition of acrylonitrile was not necessary. The reaction 
proceeded cleanly to the product in high yields (89 %). 
2.2.4 Synthesis of 9-methoxy-9-methyl-7,8,9,10-tetrahydro-
[1,4]diazepino[1,2,3-gh]purinium 2,2,2-trifluoroacetate (18) 
Early attempts to deprotect 16 using the standard procedure with trifluoroacetic acid in 
dichloromethane (1:1) produced a complicated mixture of products. Judging the outcome of the 
reaction from NMR-analysis of the crude reaction mixture was difficult and standard flash 
column chromatographic techniques on silica were problematic due to the highly polar nature of 
these compounds. To overcome this problem, a test-substrate carrying a non-reactive, lipophilic 
N-7 substituent was made to determine the appropriate reaction conditions for complete removal 
of all three Boc-groups using the least amount of potentially destructive acid. This made it 
possible to study the behavior of the Boc-groups under acidic conditions without any potential 
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interference of the N-7 oxo-butyl group. A lipophilic N-7 substituent in the test-system would 
simplify purification. 
The test-system used was the N-7 benzylated analog 19 (Scheme 35). Compound 19 was made 
from compound 15 by deprotonation with lithium hexamethyldisilazide (LiHMDS) in a mixture 
of THF and DMF at -78 ⁰C followed by addition of benzyl bromide and subsequent warming to 
room temperature.  
 
 
Scheme 34. Reagents and conditions: LiHMDS, benzyl bromide, DMF/THF, 30 min. at -78 °C then 15 min. at r.t. 
 
The procedure was taken from Dvořák et al.69 and produced high yields (85 %) of the N-7 
benzylated product 19.   
The deprotection of compound 19 with trifluoroacetic acid in dichloromethane afforded the 
oxidized compound 7-benzyladenine 21 (Scheme 36). 
 
 
Scheme 35. Reagents and conditions: a – DCM/TFA (5:1), 1 hour at  r.t.  
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It was found that stirring the tris boc-protected substrate 19 in 17 % trifluoroacetic acid in 
dichloromethane for an hour at room temperature was enough to fully deprotect the compound. 
The 8,9-dihydropurine product 20 was not isolated. Instead, the oxidized compound 21 was 
obtained in high yields (84 %). Dihydropurines bearing electron-donating substituents in the 6-
position are reportedly prone to oxidation.
93
   
The Boc-deprotection of 16 was reattempted with the same acid-concentration as used in the test-
system (Scheme 37). The reaction was performed under stringent anhydrous conditions together 
with freshly prepared molecular sieves in an attempt to produce the Schiff base 17 to increase 
lipophilicity and improve the chances of isolation.  
 
Scheme 36. Reagents and conditions: 1) DCM/TFA (5:1), Molecular sieves 3Å, 1 h at r.t. 2) MnO2, DCM/THF, 5 h 
at r.t. 3) MeOH. 
 
TLC analysis (DCM:MeOH – 9:1) of the crude reaction mixture produced two spots. Purification 
by flash column chromatography gave small amounts of compound 18 (18 %, calculated
*
) while no amount of imine 17 could be observed. It seemed that methanol from the eluent-
system had added to the imine producing the hemiaminal ether 18 as a salt of trifluoroacetic acid.  
NMR analysis of the separated second spot (by flash column chromatography on silica gel) 
showed that it contained several other compounds. Ketone 22 is likely to be one of these 
compounds. Experiments to convert compound 18 to ketone 22 by addition of water has been 
carried out, and NMR, MS and TLC analysis suggests compound 22 is produced but not as the 
sole product and separation by flash column chromatography was unsuccessful.  
                                                 
*
Yields were calculated by taking the weight of isolated material and subtracting the amount of methanol present 
based on 
1
H NMR analysis.  
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As no other methanol-free eluent-systems polar enough to move the produced compounds off the 
baseline (TLC) could be found, it was decided to add methanol to the crude in order to achieve 
full conversion to compound 18. 
Compound 18 is, however, not very stable and decomposes into several unidentified compounds 
over the course of a couple of days even under inert atmosphere. It is also highly hygroscopic and 
even deliquescent. This poses a problem when handling the compound as the water it absorbs 
from the atmosphere decomposes it. However, it is stable as a solution in methanol, showing little 
degradation after several months. Only a calculated yield of 83 % (see previous footnote
*
) has 
been achieved as methanol is still present. Evaporating the methanol completely leaves the 
compound partially decomposed. Exchange of the 9-methoxy-group is seen when leaving the 
compound in deuterated methanol.   This suggests the existence of an equilibrium between 
hemiaminal ether x and imine x which could explain the observed decomposition (Scheme 38).  
 
Scheme 37. Possible equilibrium between hemiaminal ether (18) and imine (17).  
Several attempts to convert hemiaminal ether 18 to imine 17 were unsuccessful (Scheme 39). 
Three attempts, exploiting the proposed equilibrium by using azeotropic distillation to remove 
methanol and drive the equilibrium to the right, was attempted. Since methanol is miscible in 
both toluene and dichloromethane a traditional distillation setup was used instead of the usual 
Dean-Stark apparatus. While heating with added molecular sieves 3Å, dry solvent was added at 
regular intervals.  
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Scheme 38. Reagents and conditions: a – Toluene, molecular sieves 3Å, 8 hours at 75 °C. b – Dichloromethane, 
molecular sieves 3Å, 2 hours at 50 °C. c – 4-methylbenzenesulfonic acid, toluene, 12 hours at 80 °C.  
Only partially decomposed starting material and no signs of a potential imine was observed 
(reaction a and b). An acid-catalyzed version of the azeotropic distillation was also attempted but 
resulted in severe decomposition to a wide array of unknown compounds.  
 
2.2.5 Synthesis of 9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-
gh]purine (23) 
Even if compound 17 was not obtained, it was anticipated that the hemiaminal ether 18 could act 
as a pseudoimine and display some of the reactive properties one would expect of compound 17. 
One such experiment was carried out by treating compound 18 with sodium borohydride in 
ethanol (Scheme 40). 
 
 
Scheme 39. Reagents and conditions: NaBH4, EtOH, 24 hours at r.t. 
Compound 23 was produced in very high yields (92 %). This asmarine analog has not been 
reported in the literature. 
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2.3 Sodium borohydride reductions in methanol 
During work on the reduction of compound 14a it was discovered that instead of the borane 
tetrahydrofuran complex solution used by Dvořák et al. in the reduction of Boc-protected 6-
chloropurine and 6-iodopurine,
69
 a simpler method using sodium borohydride in methanol could 
be employed.  
Sodium borohydride has seen little use in the formation of 7,8-dihydropurines in the literature. 
Maki et al. reported reducing N-benzoyl-9-benzyladenine to the corresponding 7,8-dihydropurine 
by sodium borohydride in neat acetic acid.
94
 Kelley and Linn
95
 reduced 6-chloro-2-
(trifluoromethy1)purine by sodium borohydride in refluxing THF while Pendergast and Hall
96
 
reduced several purines bearing electron-withdrawing substituents in the 6-position using sodium 
cyanoborohydride in dilute hydrochloric acid. The combination of sodium borohydride and 
methanol was used by Neiman in the reduction of 2,6-dichloro-7-methylpurine to the 8,9-
dihydropurine.
97
   
The use of sodium borohydride has some advantages over borane complexes such as BH3•THF 
and BH3•DMS. It is cheaper, easier to handle, less flammable and storable at room temperature 
without the need for stabilizers. Unlike the reported borane reactions, reductions using the 
sodium borohydride/methanol system can be carried out at room temperature in open atmosphere. 
Furthermore, all encountered side-products have been water-soluble and easily separable by 
simple extractions eliminating the need for chromatographic purification. 
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2.3.1 Synthesis of 6-methoxypurine (24) and 6-(piperidin-1-yl)purine (25) 
6-Methoxypurine (24) and 6-(piperidin-1-yl)purine (25) was prepared by nucleophilic aromatic 
substitution of 6-chloropurine (Scheme 41).  
 
 
Scheme 40. Reagents and conditions: a – (X = OMe), Na, MeOH, 24 hours at 65 °C. b – (X = piperidin-1-yl), 
Piperidine, n-BuOH, 18 hours at 100 °C.  
 
Initial attempts to synthesize 6-methoxypurine 24 were done following literature procedures.
98,99
 
The different reaction conditions attempted are listed in Table 3.No product was observed from 
entry 1 and only minor amounts of product could be spotted in the crude reaction mixture of entry 
2. Heating 6-chloropurine in a saturated solution of sodium methoxide in methanol prepared by 
adding sodium metal to methanol solved the problem (entry 3). The synthesis of compound 25 
was achieved using a modified procedure by Caldwell et al.
100
 with very high yields (95 %, entry 
4). 
Table 3. Reagents, conditions and yields for the synthesis of 6-methoxypurine (24) and 6-(piperidin-1-yl)purine (25). 
Entry X Solvent Temperature 
(°C) 
Reaction 
time (h) 
Reagent Yield 
(%) 
1 OMe DMF 
a a 
NaOMe -
 
2 OMe MeOH 65 3 NaOMe - 
3 OMe MeOH 65 24 Na 85 (24) 
4 Piperidin-1-yl n-BuOH 100 18 Piperidine 95 (25) 
a – 5 min. at 90 °C (in microwave) then 30 min. at 120 °C (in microwave) then 3 days at 110 °C (oil bath). 
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2.3.2 Protection of substituted purines 
All Boc-protections were carried out in DCM at room temperature using catalytic amounts of 
DMAP (Scheme 42).  
 
Scheme 41. Reagents and conditions: a-f – Table 4. 
 
Table 4. Reagents, conditions and yields of the Boc-protection of substituted purines. 
X Y Reaction 
time (h) 
Eq. (Boc2O) DMAP  
(mol%) 
Yield 
(%) 
Cl H 4 1.5 3.3 94 (26)
 
I H 0.75 1.5 4.0 80 (27) 
OMe H 1 2.0 4.8 78 (28) 
Piperidin-1-yl H 0.5 2.5 4.9 93 (29) 
Cl Cl 2 2.0 5.0 87 (30) 
H H 2 2.0 5.5 84
a 
(31a + 31b) 
a – Isolated as a mixture of N-9 (31a) and N-7 (31b) isomers (~1:3 respectively). 
 
Yields are generally high (78 – 94 %). All compounds showed complete N-9 selectivity except 
for purine where it appears the N-7 Boc-protected compound (31b) is the thermodynamically 
favored product. However, the reaction was not completely N-7 selective in the reaction 
timeframe. Moreover, the N-7 protected compound displayed an Rf-value identical to that of the 
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N-9 protected isomer (31a) in all eluent-systems tested. As a result, a 1:3 mixture (31a to 31b) 
was obtained after chromatographic purification on silica gel.  
In addition to the Boc-protected analogs listed in Table 4 an N-9 substituted purine 32a using a 
different protecting group was also prepared (Scheme 43). The silicon-based protecting was 
chosen as it can be cleaved under non-acidic conditions.
101
  
 
Scheme 42. Reagents and conditions: Si(Pr
i
)3OCH2Cl, Et3N, DCM, 30 min. at r.t.  
Unlike the Boc-protections, protection using (triisopropylsiloxy)methyl chloride displayed 
significantly reduced N-9 selectivity under these conditions giving a ratio of N-9 to N-7 of 
roughly 7:5.  
 2.3.3 Reduction of N-9 protected purine analogs using sodium borohydride 
in methanol. 
 
Scheme 43. Reagents and conditions: a-o – Table 5.   
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The results from the reduction of protected purine substrates using the sodium 
borohydride/methanol-system (Scheme 44) are listed in Table 5. 
Table 5. Products, conditions and yields for the NaBH4/MeOH-reduction of protected purines. 
X Y PG Eq. 
(NaBH4) 
Reaction 
time 
(min.) 
Temperature  Yield 
(%) 
Cl H Boc 2 15 r.t.
 
71  
Cl H Boc 5 20  r.t. 85  
I H Boc 2 20  r.t. 73  
I H Boc 5 20 r.t. 76  
N(Boc)2 H Boc 2 13 r.t. 81  
N(Boc)2 H Boc 5 20 r.t. 84  
OMe H Boc 2 30 r.t. -  
1-piperidinyl H Boc 2 20 r.t. n.r.
a
  
Cl Cl Boc 1.5 30 r.t. 63  
H H Boc 2 20 r.t. 69
b 
Cl H THP 1.2 120 r.t. n.r.  
Cl H THP 2 40  65 °C -  
Cl H CH
2
OSi(Pr
i
)
3
 2 300 r.t. n.r.  
a – No reaction. b – Isolated as a (1:3 mixture of N-9 to N-7).  
Boc-protected purines carrying an electron-donating group in the 6-position (x and x) did not 
produce any of the desired 7,8-dihydropurines. Compound 28 was deprotected producing 6-
methoxypurine 24 under the reaction conditions, while compound 29 failed to react at all. Purines 
protected by other groups than Boc (32a and 33) also did not produce any reduced product. 
Boc-protected purines possessing either no or an electron-withdrawing substituent in the 6-
position produce moderate to high yields of the corresponding N-9 protected 7,8-dihydropurine 
upon NaBH4/MeOH-reduction. All compounds which underwent reduction also showed some 
degree of deprotection. Increasing the equivalents of sodium borohydride seems to have a small 
positive impact on the yields. Presumably, reduction is marginally the kinetic product. 
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The observed reactivity of the Boc-protected purines can be explained by considering the nature 
of the C-6 substituent. Assuming the mechanism involves a nucleophilic attack on C-8, any 
electron-donating groups in the 6-position will contribute a partial negative charge on C-8 
(Scheme 45). 
 
Scheme 44.  
This positive mesomeric effect will repel nucleophilic attack on C-8. The stronger electron-
donating ability of the dialkylamino group compared to the alkoxy-group can also explain the 
complete lack of reactivity of compound 29 while compound 28 showed deprotection of the Boc-
group as deprotection would also involve a negative charge in the imidazole ring (Scheme 46). 
 
Scheme 45.  
Contrariwise, an electron-withdrawing group in the C-6 position will help stabilize negative 
charge in the pyrimidine ring making the imidazole ring comparably more electron-poor and 
disposed to nucleophilic attack (Scheme 47). These substrates are however still prone to 
nucleophilic deprotection. 
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Scheme 46. 
The THP-protected compound 33 did not react at room temperature. Raising the temperature to 
force the reaction only resulted in nucleophilic aromatic substitution by the solvent furbishing 6-
methoxy-9-(tetrahydropyran-2-yl)purine 42. Expected to react the same way, compound 32a was 
not tried reduced at elevated temperatures.  
Scheme 48 explains how the Boc-group facilitates reduction. Its electron-withdrawing nature 
reduces the aromatic character of the imidazole ring, decreasing the energy needed to break 
aromaticity in order to afford the 7,8-dihydropurine. 
 
Scheme 47.  
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2.3.4 Other solvents and reducing agents 
Exchanging either the solvent or the reducing agent has a dramatic effect on the reaction (Scheme 
49). Switching the solvent from methanol to THF significantly reduces the reaction rate and 
selectivity. The product is formed in the reaction, but only as a minor product along with several 
other partially deprotected isomers. The yield of reduced compound 15 was only 15 % from this 
reaction. 
 
Scheme 48. Reagents and conditions: a – NaBH4, THF,  2 days at r.t. b – Na(CN)BH3, MeOH, 3 days at r.t. then 12 
hours at reflux.  
Keeping methanol as the solvent and replacing the reducing agent to the milder sodium 
cyanoborohydride, fails to induce any of the reaction at all. The apparent lack of reactivity using 
this reducing agent might be explained by the inability/reduced tendency of the 
cyanoborohydride ion to produce reactive intermediate alkoxy hydroborates species (Scheme 16) 
by virtue of the stabilizing electron-withdrawing nitrile group. 
 
 
2.3.5 Synthesis of 3-(6-aminopurin-7-yl)propanenitrile (44a) 
Continuing to explore the scope of the N-7 alkylation methodology used in this project, also 
compound 43 (synthesized in Section 2.2.3) was used as a substrate for the deprotection-
conditions employed in Section 2.2.4. 
Applying the same conditions as used in the deprotection of the tris-boc protected 7-
benzyladenine 19, the reaction produced two major spots on TLC (Scheme 50).  
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Scheme 49. Reagents and conditions: a – TFA, DCM, 20 hours at r.t. b – TFA, MeCN, DCM, 1 hour at r.t. 
The product 44a was indeed responsible for one of the spots seen by TLC-analysis of the reaction 
mixture. The other spot proved to be compound 44b. A Ritter-type reaction had occurred,
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converting the nitrile group into a tert-butyl amide. This happens as a result of the generated 
carbocations from the deprotection of the Boc-groups which attack the nitrogen in the nitrile 
group creating the electrophilic species 45 which converts to amide 44b in the presence of water 
(Scheme 51). 
 
Scheme 50. Mechanism of the Ritter reaction. 
Although no water was present in the reaction mixture, exposure to atmospheric moisture was 
enough to convert the intermediate aminium-ion 45 to the corresponding amide 44b. 
Several reaction-conditions were tested in order to overcome this problem (Table 6). Typical 
carbocation scavengers like anisole, thioanisole and triethylsilane failed to affect the ratio of 44a 
to 44b much. One reaction was performed in water assuming that the carbocation would quickly 
be quenched producing tert-butanol. As anticipated, no amide 44b was formed; however the 
reaction produced other unwanted compounds in addition to product 44a failing to improve 
yields and complicating purification. 
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Table 6. Reagents, conditions and yields for the optimization of the synthesis of 3-(6-aminopurin-7-yl)propanenitrile 
44a. 
Solvent Reaction 
time 
(hours) 
TFA 
concentration 
(vol%) 
Additive Yield, 
44a (%) 
Yield, 
44b (%) 
Yield, 43 
(%) 
DCM 2 17 - -
a 
-
a
 - 
DCM 20 44 - 18 57 - 
DCM 20 10 - 46 32 - 
DCM 24 24 Anisole 43 24 - 
DCM 24 24 Thioanisole 22 17 - 
DCM 24 24 Triethylsilane 50 31 - 
THF 2 10
b
 H2O -
a
 - - 
MeCN 72 33 - 45 - 43 
DCM 1 24 MeCN 83 - - 
a – No yield due to impure fractions.  
b – Hydrochloric acid was used instead of TFA.  
It was found that formation of compound 44b could be avoided by adding acetonitrile to the 
mixture producing high yields of nitrile 44a (83 %). Presumably, a competition between the 
nitrile groups in the substrate and the acetonitrile for the Ritter-reaction minimized formation of 
compound 44b. Running the reaction in acetonitrile as the only solvent severely impeded the rate 
of reaction.   
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3. FURTHER RESEARCH 
Difficulties encountered in the employment of strategy e in this project (Section 2.1), were 
largely due to either the lack of nucleophilicity or the lack of acidity of the 5-amino group in the 
pyrimidine ring. The latter issue can be mitigated by starting from a formamide instead of the free 
amino-group. This could allow for cyclization to occur under Mitsunobu conditions while 
simultaneously carrying functionality able to form the five-membered ring in later stages 
(Scheme 52).   
 
Scheme 51. Possible synthetic route based on strategy e taking advantage of the acidity of the formamide group to 
achieve cyclization under Mitsunobu conditions.  
Another interesting synthetic route worth investigating is the transition metal catalyzed 
cyclization under Buchwald-Hartwig conditions depicted in Scheme 52.  
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Scheme 52. Possible synthetic route based on strategy a by cross-coupling reaction. 
 
4. CONCLUSION 
It was demonstrated that cyclization of 6-substituted pyrimidine 2 under nucleophilic 
displacement of chloride preferentially occurs on N-1 affording the pyrimido[1,6-a]pyrimidine 7. 
This is analogous to the reported results for the corresponding purine by Kashman et al.
45
   
The formed hemiaminal ether 18 in strategy b (Section 2.2) is a possible interesting intermediate 
in the synthesis of substituted THDAPs. Its ability to undergo nucleophilic addition was 
demonstrated by the introduction of a hydride substituent. Whether other nucleophiles can act 
similarly remains to be seen.  
A novel methodology for the reduction of electron-poor, N-9 Boc-protected purines forming 
important 7,8-dihydropurine intermediates was discovered employing the cheap and easy to 
handle reagent sodium borohydride under mild conditions. This is an important step in the 
synthesis of N-7 alkylated purines.  
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5. EXPERIMENTAL 
1
H NMR spectra were recorded at 600 MHz with a Bruker AV600 instrument or a Bruker 
AVII600 instrument, at 500 MHz with a Bruker DRX500 instrument, at 400 MHz with a Bruker 
AVII400 instrument or at 200 MHz with a Bruker DPX200 instrument. The decoupled 
13
C NMR 
spectra were recorded at 150, 125 or 100 MHz using the instruments mentioned above. All J-
values are reported in Hertz. Mass spectra, under electron impact conditions, were recorded with 
a VG Prospec instrument at 70 eV ionizing voltage, and are presented as m/z (% rel. int.). 
HRMS-EI was performed with a double-focusing magnetic sector instrument mentioned above. 
Microwave experiments were carried out in sealed vessels in a synthesis reactor Monowave 300, 
Anton Paar GmbH, equipped with a Ruby thermometer and internal IR probe. Melting points 
were determined with a Büchi Melting Point B-545 apparatus and are uncorrected. Flash 
chromatography was performed on silica gel (Merck no. 09385). Dry DCM, THF, DMF and 
MeCN were obtained from solvent purification system, MB SPS-800 from MBraun, Garching, 
Germany. Hexanes were distilled before use. All other solvents and reagents were commercially 
available and used as received. 
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Synthesis of 3-((5-amino-6-chloropyrimidin-4-yl)amino)propan-1-ol (2) 
 
5-Amino-4,6-dichloropyrimidine (0.852 g, 5.20 mmol) and 3-amino-1-propanol (1.17 g, 15.6 
mmol) were dissolved in 1,4-dioxane (10 ml) and stirred at 90 °C for 20 hours. The solvent was 
removed in vacuo and the resulting red/brown oil was purified by flash column chromatography 
(DCM:MeOH – 93:7) affording a pale yellow solid.  
Yield 973 mg (92 %) (lit. 80 – 81 %). 
1
H NMR (DMSO-d6, 400 MHz): δ 7.72 (s, 1H, 2), 6.77 (t, J = 5.2 Hz, 1H, 7), 5.00 (s, 2H, 8), 
4.49 (t, J = 5.1 Hz, 1H, 13), 3.50-3.45 (m, 2H, 12), 3.45-3.40 (m, 2H, 10), 1.71 (p, J = 6.7 Hz, 
2H, 11). 
 
13
C NMR (DMSO-d6, 100 MHz): δ 152.08 (6), 145.69 (2), 136.58 (4), 123.39 (5), 58.42 (12), 
38.06 (10), 32.01 (11). 
 
MS EI m/z (rel. %): 204/202 (20/60, M
+
), 186/184 (3/11), 173/171 (24/72), 159/157 (45/100), 
146/144 (15/47), 94 (28). 
  
HR-MS Found 202.0626 calcd. for C7H11ClN4O 202.0621. 
  
M.p., 106 °C, (86 – 87 °C as monohydrate (lit. 86 – 87 °C)). 
 
Compound known in literature.
82
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Spectrum 1. 
1
H NMR (DMSO-d6, 400 MHz) of 3-((5-amino-6-chloropyrimidin-4-yl)amino)propan-1-ol (2). 
 
Spectrum 2. 
13
C NMR (DMSO-d6, 100 MHz) of 3-((5-amino-6-chloropyrimidin-4-yl)amino)propan-1-ol (2). 
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Synthesis of 8-chloro-3,4-dihydropyrimido[1,6-a]pyrimidin-9-amine hydrochloride (7) 
 
3-((5-amino-6-chloropyrimidin-4-yl)amino)propan-1-ol (2) (400 mg, 1.97 mmol) was dissolved 
in THF (20 mL). Under an atmosphere of argon, the solution was cooled to 0 ⁰C and thionyl 
chloride (430 μL, 5.92 mmol) was added dropwise through the septum over 5 min. The reaction 
mixture was stirred for 1 hour before it was allowed to warm to room temperature. The mixture 
was then stirred for an additional 1.5 hours at room temperature before the volatiles were 
removed in vacuo. The crude reaction mixture was dissolved in THF (30 mL) and MeOH (2 mL) 
and stirred at room temperature for three days before the volatiles were removed in vacuo 
affording 437 mg (quantitative) product as a brown powder. 
1
H NMR (DMSO-d6, 500 MHz): δ 10.68 (bs, 1H, 12), 8.01 (s, 1H, 2), 6.55 (s, 2H, 7), 4.22 (t, J = 
5.5 Hz, 2H, 11), 3.50 (t, J = 5.6 Hz, 2H, 9), 2.09 (m, 2H, 10).  
  
13
C NMR (DMSO-d6, 125 MHz): δ 17.06 (10), 38.71 (9), 47.12 (11), 126.40 (5), 130.99 (4), 
137.14 (2), 144.87 (6).  
MS EI m/z (rel. %): 187/185 (9/71, M
+
), 186/184 (23/81), 157 (100). 
  
HR-MS Found 184.0515 calcd. for C7H9ClN4 184.0516.  
  
M.p. 269 ⁰C – 272 ⁰C (dec.). 
Compound not known in literature. 
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Spectrum 3. 
1
H NMR (DMSO-d6, 500 MHz) of 8-chloro-3,4-dihydropyrimido[1,6-a]pyrimidin-9-amine 
hydrochloride (7). 
 
Spectrum 4. 
13
C NMR (DMSO-d6, 125 MHz) of 8-chloro-3,4-dihydropyrimido[1,6-a]pyrimidin-9-amine 
hydrochloride (7). 
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 Synthesis of 3-((5-amino-6-chloropyrimidin-4-yl)(methyl)amino)propan-1-ol (10) 
 
5-Amino-4,6-dichloropyrimidine (1) (351 mg, 2.14 mmol) and 3-methylamino-1-propanol (624 
μL, 6.42 mmol) was dissolved in 1,4-dioxane (30 mL) and heated to reflux for 20 hours under 
argon atmosphere while stirring. The solvent was removed in vacuo and the crude reaction 
mixture was purified by flash column chromatography (DCM:MeOH 10:0 to 19:1 gradient) 
affording an off-white powder.  
Yield 443.4 mg (96 %).  
 
1
H NMR (DMSO-d6, 400 MHz): δ 7.90 (s, 1H, 2), 5.09 (bs, 2H, 7), 3.46 (t, 2H, 11), 3.33 (t, 2H, 
9), 2.86 (s, 3H, 14), 1.70 (p, 2H, 10). 
 
13
C NMR (DMSO-d6, 100 MHz): δ 155.58 (6), 144.86 (2), 141.06 (4), 128.23 (5), 57.76 (11), 
46.87 (9), 36.66 (14), 29.48 (10). 
 
MS EI m/z (rel. %): 218/216 (10/30, M
+
), 185 (13), 173/171 (32/100), 159 (12), 143 (9), 130 (5). 
  
HR-MS Found 216.0771 calcd. for C8H13ClN4O 216.0778. 
  
M.p. 69 °C – 70 °C.  
 
Compound not known in literature.  
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Spectrum 5. . 
1
H NMR (DMSO-d6, 400 MHz) of 3-((5-amino-6-chloropyrimidin-4-yl)(methyl)amino)propan-1-ol 
(10). 
 
Spectrum 6. . 
13
C NMR (DMSO-d6, 100 MHz) of 3-((5-amino-6-chloropyrimidin-4-yl)(methyl)amino)propan-1-ol 
(10). 
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Synthesis of 9-amino-8-chloro-1-methyl-1,2,3,4-tetrahydropyrimido[1,6-a]pyrimidinium 
chloride (11) 
 
3-((5-amino-6-chloropyrimidin-4-yl)(methyl)amino)propan-1-ol (10) (125 mg, 0.576 mmol) was 
dissolved in THF (30 mL), put under argon atmosphere and cooled to 0 ⁰C. Thionyl chloride (42 
μL, 0.60 mmol) was added dropwise to the solution over 5 min. The reaction mixture was stirred 
90 min. at 0 ⁰C before it was warmed to room temperature and stirred for an additional 1 hour. 
The volatiles were removed in vacuo affording 140 mg of a viscous brown oil of impure 
compound.  
1
H NMR (DMSO-d6, 400 MHz): δ 8.24 (s, 1H, 2), 5.80 (bs, 2H, 7), 4.22 (t, J = 5.1 Hz, 2H, 11), 
3.49 (t, J = 6.1 Hz, 2H, 9), 3.39 (s, 3H, 12), 2.18 (m, 2H, 10).  
 
13
C NMR (DMSO-d6, 100 MHz): δ 147.19 (6), 138.85 (2), 138.38 (4), 129.11 (5), 51.17 (9), 
48.43 (11), 40.12 (12), 20.03 (10). 
 
MS ESI m/z (rel. %): 199 (100, M
+
).  
  
HR-MS Found 199,0754 calcd. for C8H12ClN4 199.0750. 
  
M.p. >250 °C 
 
Compound not known in literature.  
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Spectrum 7. 
1
H NMR (DMSO-d6, 400 MHz) of 9-amino-8-chloro-1-methyl-1,2,3,4-tetrahydropyrimido[1,6-
a]pyrimidinium chloride (11). 
 
Spectrum 8. 
13
C NMR - APT (DMSO-d6, 100 MHz) of 9-amino-8-chloro-1-methyl-1,2,3,4-tetrahydropyrimido[1,6-
a]pyrimidinium chloride (11). 
66 
 
Synthesis of tritert-butyl 9,10,10-adenineetricarboxylate (14a) 
 
Adenine (13) (1.36 g, 10.0 mmol) and 4-dimethylaminopyridine (122 mg, 0.996 mmol) was 
suspended in THF (50 mL). Di-tert-butyl dicarbonate (8.51 g, 39.0 mmol) was added to the 
suspension under an atmosphere of argon and the mixture was stirred at room temperature for 22 
hours before the volatiles were removed in vacuo and the crude reaction mixture purified by flash 
column chromatography (hexanes:ethyl acetate – 7:3) affording a colorless solid. 
Yield 3.98 g (91 %) (lit. 90 %). 
1
H NMR (CDCl3, 400 MHz): δ 8.99 (s, 1H, 2), 8.48 (s, 1H, 8), 1.69 (s, 9H, 16), 1.41 (s, 18H, 
13). 
13
C NMR (CDCl3, 125 MHz): δ 154.21 (2), 152.59 (4), 151.34 (6), 150.16 (11), 145.76 (14), 
143.30 (8), 129.72 (5), 87.61 (15), 84.09 (12), 28.07 (16), 27.88 (13). 
 
MS EI m/z (rel. %): 435 (1, M
+
), 236 (3), 161 (46), 135 (88), 57 (60), 41 (100).  
  
HR-MS Found 435.2121 calcd. for C20H29N5O6 435.2118. 
  
M.p. 54 – 55 °C (lit. 54 – 55 °C68). 
 
Compound known in literature.
68
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Spectrum 9. 
1
H NMR (CDCl3, 400 MHz) of tritert-butyl 9,10,10-adenineetricarboxylate (14). 
 
Spectrum 10. 
13
C NMR (CDCl3, 150 MHz) of tritert-butyl 9,10,10-adenineetricarboxylate (14). 
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Synthesis of tert-butyl 6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-carboxylate (15)  
 
 
Reduction using borane-tetrahydrofuran complex: 
Tritert-butyl-9,10,10-adenineetricarboxylate (14) (2.28 g, 5.21 mmol) was dissolved in THF (20 
mL) and cooled to -78 ⁰C on a dry ice/acetone bath under argon atmosphere. Borane 
tetrahydrofuran complex 1 M solution (7.30 mL, 7.30 mmol) was added through the septum and 
the mixture was stirred for 2 hours before it was warmed to room temperature and stirred for 
another 18 hours. The reaction mixture was quenched with saturated aqueous ammonium 
chloride (20 mL) and stirred vigorously for 1 hour. The phases were separated and the aqueous 
phase was extracted with DCM (3 x 10 mL). The combined organic phases were dried over 
MgSO4, filtered and evaporated in vacuo. The crude product was purified by flash column 
chromatography (hexanes:ethyl acetate – 100:0 to 75:25 gradient) affording a colorless powder.  
Yield 1.79 g (78 %). 
Reduction using sodium borohydride in methanol: 
Tritert-butyl-9,10,10-adenineetricarboxylate (14) (1.03 g, 2.37 mmol) was dissolved in MeOH 
(50 mL) and NaBH4 (446 mg, 11.8 mmol) was added. The reaction was stirred for 20 min. before 
water (20 mL) was added and the mixture concentrated in vacuo until a white precipitate was 
formed. DCM (15 mL) and NaCl (0.5 g) was added and the phases were separated. The aqueous 
layer was extracted with DCM (3 x 10 mL) and the combined organic layers were dried over 
MgSO4, filtered and evaporated in vacuo to afford a colorless solid. 
Yield 868 mg (84 %). 
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1
H NMR (CDCl3, 500 MHz): δ 8.26 (s, 1H, 2), 5.24 (s, 2H, 8), 4.15 (bs, 1H, 7), 1.54 (s, 9H, 16), 
1.47 (s, 18H, 13). 
13
C NMR (CDCl3, 150 MHz): 156.80 (4), 150.27 (11), 149.86 (2), 148.67 (14), 137.88 (6), 
126.58 (5), 84.24 (12), 83.50 (15), 64.68 (8), 28.29 (16), 27.96 (13). 
 
MS EI m/z (rel. %): 437 (7, M
+
), 337 (11), 263 (7), 237 (15), 181 (38), 163 (85), 137 (40), 136 
(38), 119 (8), 57 (100), 41 (45).  
 HR-MS Found 437.2269 calcd. for C20H31N5O6 437.2274. 
 M.p. >250 °C (dec.) 
Compound not known in literature.  
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Spectrum 11. 
1
H NMR (CDCl3, 500 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-
carboxylate (15). 
 
Spectrum 12. 
13
C NMR (CDCl3, 150 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-
carboxylate (15). 
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Synthesis of tert-butyl 6-(ditert-butoxycarbonylamino)-7-(3-oxobutyl)-8,9-dihydropurine-9-
carboxylate (16) 
 
tert-Butyl 6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-carboxylate (15) (480 mg, 1.10 
mmol) was dissolved in MeCN (30 mL) under an atmosphere of argon. 1,8-
Diazabicyclo[5.4.0]undec-7-ene (180 μL, 1.21 mmol) was added through the septum. But-3-en-2-
one (183 μL, 2.20 mmol) was dissolved in MeCN (3.5 mL) and added slowly to the reaction 
mixture with a syringe pump at 0.75 mL/h. After addition the volatiles were removed in vacuo 
and the resulting brown oil was purified by flash column chromatography (hexanes/ethyl acetate 
– 7:3 to 1:1 gradient) affording a colorless solid.  
Yield 436 mg (78 %). 
1
H NMR (CDCl3, 400 MHz): δ 8.20 (s, 1H, 2), 5.15 (s, 2H, 8), 3.43 (t, J = 6.6 Hz, 2H, 17), 2.73 
(t, J = 6.6 Hz, 2H, 18), 2.14 (s, 3H, 20), 1.55 (s, 9H, 16), 1.44 (s, 18H, 13). 
13
C NMR (CDCl3, 150 MHz): δ 206.30 (19), 156.59 (4), 150.73 (14), 148.42 (2), 148.18 (11), 
134.52 (6), 128.83 (5), 83.96 (12), 83.80 (15), 69.32 (8), 42.03 (17), 41.94 (18), 30.28 (20), 28.24 
(16), 28.04 (13). 
 
MS EI m/z (rel. %): 507 (7, M
+
), 407 (11), 233 (69), 175 (53), 162 (33), 136(15), 119 (11), 57 
(97), 41 (100). 
 HR-MS Found 507.2686 calcd. for C24H37N5O7 507.2693. 
 M.p. >133 °C (dec.). 
Compound not known in literature.  
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Spectrum 13. 
1
H NMR (CDCl3, 400 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-7-(3-oxobutyl)-8,9-
dihydropurine-9-carboxylate (16). 
 
Spectrum 14. 
13
C NMR (CDCl3, 150 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-7-(3-oxobutyl)-8,9-
dihydropurine-9-carboxylate (16). 
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Synthesis of tert-butyl 7-(2-cyanoethyl)-6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-
9-carboxylate (43) 
 
tert-Butyl 6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-carboxylate (15) (853 mg, 1.94 
mmol) was dissolved in MeCN (30 mL) under an atmosphere of argon. 1,8-
Diazabicyclo[5.4.0]undec-7-ene (320 μL, 2.14 mmol) and acrylonitrile (255 μL, 3.89 mmol) was 
added to the reaction mixture. The reaction mixture was stirred for 5 hours before the volatiles 
were removed in vacuo and the resulting yellow oil purified by flash column chromatography 
(hexanes/ethyl acetate – 7:3) affording a colorless solid.  
Yield 843 mg (89 %). 
1
H NMR (CDCl3, 400 MHz): δ 8.28 (s, 1H, 2), 5.27 (s, 2H, 8), 3.51 (t, J = 6.9 Hz, 2H, 17), 2.62 
(t, J = 6.9 Hz, 2H, 18), 1.56 (s, 9H, 16), 1.45 (s, 18H, 13). 
13
C NMR (CDCl3, 125 MHz): δ 156.54 (4), 150.61 (14), 149.72 (2), 148.01 (11), 135.74 (6), 
127.79 (5), 117.39 (19), 84.56 (12), 84.32 (15), 69.07 (8), 44.32 (17), 28.25 (16), 28.04 (13), 
16.97 (18). 
 
MS EI m/z (rel. %): 490 (2, M
+
), 390 (5), 216 (100), 215 (57), 190 (8), 176 (63), 174 (19), 161 
(6), 119 (8). 
 HR-MS Found 490.2555 calcd. for C23H34N6O6 490.2540. 
 M.p. >134 °C (dec.). 
Compound not known in literature.  
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Spectrum 15. 
1
H NMR (CDCl3, 400 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-7-(2-cyanoethtyl)-8,9-
dihydropurine-9-carboxylate (43). 
 
Spectrum 16. . 
13
C NMR (CDCl3, 125 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-7-(3-cyanoethyl)-8,9-
dihydropurine-9-carboxylate (43). 
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Synthesis of tert-butyl 6-chloropurine-9-carboxylate (26) 
 
6-Chloropurine (502 mg, 3.25 mmol) and 4-dimethylaminopyridine (13.0 mg, 0.106 mmol) was 
suspended in DCM (6 mL). Di-tert-butyl dicarbonate (1.05 g, 4.82 mmol) was dissolved in DCM 
(4 mL) and added to the reaction flask. The mixture was stirred for 4 hours before the volatiles 
were removed in vacuo. The crude material was purified by flash column chromatography 
(hexanes:ethyl acetate – 8:2 to 65:35) affording a colorless solid. 
Yield 777 mg (94 %). 
1
H NMR (CDCl3, 600 MHz): δ 8.86 (s, 1H, 2), 8.52 (s, 2H, 8), 1.67 (s, 9H, 12). 
 
13
C NMR (CDCl3, 150 MHz): δ 154.05, 152.11, 151.19, 145.45, 143.95, 132.56, 88.13, 77.16, 
28.01. 
 
MS EI m/z (rel. %): 254 (3, M
+
), 239 (6), 181 (8), 157 (7), 156 (15 (, 155 (22), 154 (41), 119 
(22), 57 (100). 
HR-MS Found 254.0573 calcd. for C10H11ClN4O2 254.0571. 
M.p. >110 °C (dec.). 
Compound known in literature.
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Spectrum 17. 
1
H NMR (CDCl3, 600 MHz) of tert-butyl 6-chloropurine-9-carboxylate (26). 
 
Spectrum 18. 
13
C NMR (CDCl3, 150 MHz) of tert-butyl 6-chloropurine-9-carboxylate (26). 
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Synthesis of tert-butyl 6-iodopurine-9-carboxylate (27) 
 
6-Iodopurine (127 mg, 0.518 mmol) was dissolved in DCM (10 mL) and 
4-dimethylaminopyridine (2.5 mg, 0.0205 mmol) was added. Di-tert-butyl dicarbonate (167 mg, 
0.767 mmol) was dissolved in DCM (5 mL) and added to the reaction flask. The mixture stirred 
for 45 minutes before removing the volatiles in vacuo. The residue was purified by flash column 
chromatography (hexanes:ethyl acetate – 75:25) affording a colorless solid.  
Yield 144 mg (80 %). 
1
H NMR (CDCl3, 600 MHz): δ 8.75 (s, 1H, 2), 8.53 (s, 2H, 8), 1.68 (s, 9H, 12). 
 
13
C NMR (CDCl3, 150 MHz): δ 154.03 (2), 147.56 (4), 145.69 (10), 143.31 (8), 139.41 (5), 
123.06 (6), 88.14 (11), 28.06 (12). 
 
MS EI m/z (rel. %): 346 (7, M
+
), 247 (15), 246 (85), 119 (100), 92 (16), 65 (19), 57 (60). 
HR-MS Found 345.9938 calcd. for C10H11IN4O2 345.9927. 
M.p. >111 °C (dec.). 
Compound known in literature.
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Spectrum 19. 
1
H NMR (CDCl3, 600 MHz) of tert-butyl 6-iodopurine-9-carboxylate (27). 
 
Spectrum 20. 
13
C NMR (CDCl3, 150 MHz) of tert-butyl 6-iodopurine-9-carboxylate (27). 
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Synthesis of tert-butyl 6-methoxypurine-9-carboxylate (28) 
 
6-Methoxypurine (151 mg, 1.01 mmol) and 4-dimethylaminopyridine (5.9 mg, 0.048 mmol) was 
suspended in DCM (10 mL). Di-tert-butyl dicarbonate (439 mg, 2.01 mmol) was dissolved in 
DCM (5 mL) and added to the reaction flask. The mixture was stirred for 1 hour before removing 
the volatiles in vacuo. The residue was purified by flash column chromatography (hexanes:ethyl 
acetate – 1:1) affording a colorless solid.  
Yield 196 mg (78 %). 
1
H NMR (CDCl3, 500 MHz): δ 8.67 (s, 1H, 2), 8.33 (s, 2H, 8), 4.17 (s, 3H, 13), 1.67 (s, 9H, 12). 
 
13
C NMR (CDCl3, 125 MHz): δ 161.49, 154.33, 151.55, 145.92, 141.13, 122.38, 87.18, 77.16, 
54.59, 28.07. 
 
MS EI m/z (rel. %): 250 (15, M
+
), 235 (9), 177 (15), 151 (15), 150 (73), 149 (32), 121 (22), 120 
(31), 93 (18), 57 (100). 
HR-MS Found 250.1071 calcd. for C11H14N4O3 250.1066. 
M.p. 94 – 95 °C.  
Compound not known in literature.  
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Spectrum 21. 
1
H NMR (CDCl3, 500 MHz) of tert-butyl 6-methoxypurine-9-carboxylate (28). 
 
Spectrum 22. 
13
C NMR (CDCl3, 125 MHz) of tert-butyl 6-methoxypurine-9-carboxylate (28). 
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Synthesis of tert-butyl 6-(piperidin-1-yl)purine-9-carboxylate (29) 
 
6-(Piperidin-1-yl)purine (165 mg, 0.809 mmol) and 4-dimethylaminopyridine (4.9 mg, 0.040 
mmol) was suspended in DCM (10 mL). Di-tert-butyl dicarbonate (439 mg, 2.01 mmol) was 
dissolved in DCM (5 mL) and added to the reaction flask. The mixture stirred for 30 minutes 
before removing the volatiles in vacuo. The residue was purified by flash column 
chromatography (hexanes:ethyl acetate – 7:3) affording a colorless solid.  
Yield 228 mg (93 %). 
1
H NMR (CDCl3, 200 MHz): δ 8.43 (s, 1H, 2), 8.11 (s, 2H, 8), 4.19 (m, 4H, 13), 1.69 (m, 6H, 
14), 1.65 (s, 9H, 12). 
 
13
C NMR (CDCl3, 100 MHz): δ 154.54, 154.07, 151.02, 146.30 , 136.77, 120.32, 86.30 , 46.62, 
28.12, 26.22, 24.91. 
 
MS EI m/z (rel. %): 303 (10, M
+
), 203 (100), 188 (14), 174 (72), 160 (30), 148 (31), 135 (20), 
120 (29), 93 (16), 84 (13). 
HR-MS Found 303.1687 calcd. for C15H21N5O2 303.1695. 
M.p. 73 – 74 °C. 
Compound not known in literature.  
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Spectrum 23. 
1
H NMR (CDCl3, 200 MHz) of tert-butyl 6-(piperidin-1-yl)purine-9-carboxylate (29). 
 
Spectrum 24. 
13
C NMR (CDCl3, 100 MHz) of tert-butyl 6-(piperidin-1-yl)purine-9-carboxylate (29). 
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Synthesis of tert-butyl 2,6-dichloropurine-9-carboxylate (30) 
 
2,6-Dichloropurine (252 mg, 1.33 mmol) and 4-dimethylaminopyridine (8.0 mg, 0.066 mmol) 
was suspended in DCM (10 mL). Di-tert-butyl dicarbonate (584 mg, 2.68 mmol) was dissolved 
in DCM (5 mL) and added to the reaction flask. The mixture stirred for 2 hours before removing 
the volatiles in vacuo. The residue was purified by flash column chromatography (hexanes:ethyl 
acetate – 8:2) affording a colorless solid.  
Yield 336 mg (87 %). 
1
H NMR (CDCl3, 500 MHz): δ 8.52 (s, 1H, 8), 1.69 (s, 9H, 12). 
 
13
C NMR (CDCl3, 125 MHz): δ 155.36 (10), 152.88 (2), 152.21 (4), 145.14 (6), 144.45 (8), 
131.76 (5), 88.66 (11), 28.02 (12). 
 
MS EI m/z (rel. %): 290/288 (1/2, [M+2]
+
/M
+
), 215 (6), 192 (6), 191 (10), 190 (38), 188 (57), 
155 (7), 153 (22), 92 (7), 57 (100). 
HR-MS Found 288.0191 calcd. for C10H10Cl2N4O2 288.0181. 
M.p. X °C. 
Compound not known in literature.  
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Spectrum 25. 
1
H NMR (CDCl3, 500 MHz) of tert-butyl 2,6-dichloropurine-9-carboxylate (30). 
 
Spectrum 26. 
13
C NMR (CDCl3, 125 MHz) of tert-butyl 2,6-dichloropurine-9-carboxylate (30). 
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Synthesis of tert-butyl purine-9-carboxylate (31a) and tert-butyl purine-7-carboxylate (31b) 
 
Purine (77 mg, 0.64 mmol) and 4-dimethylaminopyridine (4.3 mg, 0.035 mmol) was suspended 
in DCM (5 mL). Di-tert-butyl dicarbonate (281 mg, 1.29 mmol) was dissolved in DCM (3 mL) 
and added to the reaction flask. The mixture stirred for 2 hours before removing the volatiles in 
vacuo. The residue was purified by flash column chromatography (hexanes:ethyl acetate – 25:75) 
affording a colorless solid.  
Yield 118 mg (84 %). 
1
H NMR (CDCl3, 500 MHz): δ 9.33, 9.20, 9.18, 9.14, 8.74, 8.53, 7.24, 1.71, 1.70. 
 
13
C NMR (CDCl3, 100 MHz): δ 161.62, 154.90, 154.65, 150.94, 149.44, 146.84, 146.55, 145.82, 
144.04, 143.78, 134.87, 123.25, 88.08, 87.52, 77.16, 28.10, 28.07. 
 
MS EI m/z (rel. %): 220 (11, M
+
), 147 (10), 120 (84), 93 (17), 66 (23), 57 (100). 
HR-MS Found 220,0956 calcd. for C10H12N4O2 220.0960. 
M.p. 145 °C. 
Compounds not known in literature.  
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Spectrum 27. 
1
H NMR (CDCl3, 500 MHz) of tert-butyl purine-9-carboxylate (x) and tert-butyl purine-7-carboxylate 
(31ab). 
 
Spectrum 28. 
13
C NMR (CDCl3, 100 MHz) of tert-butyl purine-9-carboxylate (x) and tert-butyl purine-7-
carboxylate (31ab). 
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Synthesis of tert-butyl 6-chloro-7,8-dihydropurine-9-carboxylate (34) 
 
tert-Butyl 6-chloropurine-9-carboxylate (26) (934  mg, 3.67 mmol) was dissolved in MeOH (50 
mL) and set to vigorous stirring. Sodium borohydride (695 mg, 18.4 mmol) was added and the 
mixture stirred for 20 minutes before water (20 mL) was added. The mixture was concentrated in 
vacuo until a white precipitate was formed. DCM (15 mL) and sodium chloride (0.5 g) was added 
to the suspension, shaken and transferred to a separation funnel. The layers were separated and 
the water-phase extracted with DCM (3 x 10 mL). The combined organic layers were dried over 
MgSO4, filtered and evaporated in vacuo to afford a colorless solid. 
Yield 800 mg (85 %). 
1
H NMR (CDCl3, 200 MHz): δ 8.16 (s, 1H, 2), 5.33 (s, 2H, 8), 3.85 (br s, 1H, 7), 1.55 (s, 9H, 
12). 
 
13
C NMR (CDCl3, 150 MHz): δ 154.72 (4), 149.50 (2), 148.49 (10), 134.13 (6), 131.00 (5), 
84.20 (11), 64.68 (8), 28.27 (12). 
 
MS EI m/z (rel. %): 256 (7, M
+
), 183 (7), 158/156 (17/60), 157/155 (35/100), 119 (48), 92 (7), 67 
(6), 57 (70). 
HR-MS Found 256.0726 calcd. for C10H13ClN4O2 256.0727. 
M.p. >185 °C (dec.) (lit. >185 °C (dec.)). 
Compound known in literature.
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Spectrum 29. 
1
H NMR (CDCl3, 200 MHz) of tert-butyl 6-chloro-7,8-dihydropurine-9-carboxylate (34). 
 
Spectrum 30. 
13
C NMR (CDCl3, 100 MHz) of tert-butyl purine-9-carboxylate (34). 
89 
 
Synthesis of tert-butyl 7-benzyl-6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-
carboxylate (19) 
 
Lithium hexamethyldisilazide (615 µL, 1 M in THF, 0.615 mmol) was added over a period of 5 
min to a stirring solution of compound 15 (256 mg, 0.585 mmol) in DMF (7 mL) and THF (3 
mL) under argon-atmosphere at -78 °C. After stirring for 10 min., benzyl bromide (105 µL, 0.884 
mmol) was added dropwise over a period of 5 min. After stirring for an additional 10 min., the 
mixture was allowed to warm to room temperature and stirred for 15 min. before sat. aq. NH4Cl 
(8 mL) and EtOAc (15 mL) were added. The layers were separated and the water phase extracted 
with EtOAc (3 x 10 mL). The combined organic phases were washed with brine (2 x 6 mL), dried 
(MgSO4) and evaporated in vacuo. The crude product was purified by flash column 
chromatography (EtOAc:hexanes – 1:4) affording a colorless solid. 
Yield 262 mg (85 %). 
1
H NMR (CDCl3, 400 MHz): δ 8.24 (s, 1H, 2), 7.35-7.26 (m, 5H, 19/20/21), 4.98 (s, 2H, 8), 4.41 
(s, 2H, 17), 1.50 (s, 9H, 16), 1.40 (s, 18H, 13). 
13
C NMR (CDCl3, 100 MHz): δ 156.23 (4), 150.45 (11), 148.38 (14), 148.24 (2), 135.55 (18), 
134.41 (6), 129.16 (5), 129.06 (20), 128.27 (21), 127.98 (19), 83.93 (12), 83.90 (15), 68.08 (8), 
51.05 (17), 28.24 (16), 28.06 (13). 
 
MS EI m/z (rel. %): 527 (2, M
+
), 427 (3), 253 (34), 251 (39), 91 (100). 
HR-MS Found 527.2733 calcd. for C27H37N5O6 527.2744. 
M.p. 49 – 50 °C.                                                                      Compound not known in literature. 
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Spectrum 31. 
1
H NMR (CDCl3, 400 MHz) of tert-butyl 7-benzyl-6-(ditert-butoxycarbonylamino)-8,9-
dihydropurine-9-carboxylate (19). 
 
Spectrum 32. 
13
C NMR (CDCl3, 100 MHz) of tert-butyl 7-benzyl-6-(ditert-butoxycarbonylamino)-8,9-
dihydropurine-9-carboxylate (19). 
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Synthesis of 7-benzylpurin-6-amine (21) 
 
Tert-Butyl 7-benzyl-6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-carboxylate (19) (185 
mg, 0.351 mmol) was dissolved in DCM (5 mL) and the reaction flask flushed with argon. 
Trifluoroacetic acid (1.00 mL, 13.0 mmol) was added and the mixture was stirred for 1 hour 
before the volatiles were removed in vacuo. The crude product was purified by flash column 
chromatography (DCM:MeOH – 9:1) affording a grey solid. 
Yield 67 mg (85 %). 
1
H NMR (CDCl3, 600 MHz): δ 8.42 (s, 1H, 8), 8.18 (s, 1H, 2), 7.33 (t, J = 7.4 Hz, 2H, 14), 7.27 
(t, J = 7.4 Hz, 1H, 15), 7.14 (d, J = 7.4 Hz, 2H, 13), 6.81 (s, 2H, 10), 5.68 (s, 2H, 11). 
 
13
C NMR (CDCl3, 150 MHz): δ 160.18 (4), 152.39 (2), 151.45 (6), 146.34 (8), 137.47 (12), 
128.78 (14), 127.79 (15), 126.63 (13), 110.78 (5), 49.01 (11). 
 
 
MS ESI m/z (rel. %): 226 ([M+H]
+
), 248 ([M+Na]
+
). 
HR-MS Found 226.1089 calcd. for C12H12N5 226.1087. 
M.p. >220 °C (dec.). 
Compound known in literature.
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92 
 
 
Spectrum 33. 
1
H NMR (DMSO-d6, 600 MHz) of 7-benzylpurin-6-amine (21). 
 
Spectrum 34. 
13
C NMR (DMSO-d6, 150 MHz) of 7-benzylpurin-6-amine (21). 
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Synthesis of 3-(6-aminopurin-7-yl)propanenitrile (44a) 
 
tert-Butyl 7-(2-cyanoethyl)-6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-carboxylate 
(43) (122 mg, 0.249 mmol) was dissolved in DCM (4.75 mL) and acetonitrile (0.25 mL) was 
added. Trifluoroacetic acid (1.2 mL) was added over a period of 1 min. under an atmosphere of 
argon. The mixture was stirred for 1 hour before adding acetonitrile (5 mL) and removing the 
volatiles in vacuo. The residue was purified by flash column chromatography (DCM:MeOH – 
9:1) affording an off-white powder.  
Yield 39 mg (83 %). 
1
H NMR (DMSO-d6, 400 MHz): δ 8.32 (s, 1H, 8), 8.21 (s, 1H, 2), 7.01 (s, J = 6.6 Hz, 2H, 13), 
4.70 (t, J = 6.6 Hz, 2H, 10), 2.99 (t, 2H, 11). 
 
13
C NMR (DMSO-d6, 100 MHz): δ 160.07 (4), 152.45 (2), 151.28 (6), 145.97 (8), 117.93 (12), 
110.46 (5), 41.64 (10), 20.57 (11). 
 
MS EI m/z (rel. %): 188 (3, M
+
), 135 (10), 108 (24), 81 (4), 66 (1), 53 (25). 
HR-MS Found 188.0813 calcd. for C8H8N6 188.0810. 
M.p. >300 °C (lit. >300 °C). 
Compound known in literature.
44
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Spectrum 35. 
1
H NMR (DMSO-d6, 400 MHz) of 3-(6-aminopurin-7-yl)propanenitrile (44a). 
 
Spectrum 36. 
13
C NMR (DMSO-d6, 100 MHz) of 3-(6-aminopurin-7-yl)propanenitrile (44a). 
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Synthesis of 3-(6-aminopurin-7-yl)-N-(tert-butyl)propanamide(44b) 
 
tert-Butyl 7-(2-cyanoethyl)-6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-carboxylate 
(43) (248 mg, 0.505 mmol) was dissolved in DCM (5 mL). Trifluoroacetic acid (4.0 mL) was 
added over a period of 1 min. under an atmosphere of argon. The mixture was stirred for 20 hours 
before removing the volatiles in vacuo. The residue was purified by flash column 
chromatography (DCM:MeOH – 9:1) affording an off-white powder.  
Yield 75 mg (57 %). 
1
H NMR (MeOH-d4, 600 MHz): δ 8.23 (s, 1H, 2), 8.18 (s, 1H, 8), 4.66 (t, J = 6.2 Hz, 2H, 10), 
2.70 (t, J = 6.2 Hz, 2H, 11), 1.20 (s, 9H, 15). 
 
13
C NMR (MeOH-d4, 150 MHz): δ 171.23 (12), 160.16 (4), 153.66 (6), 153.60 (2), 147.56 (8), 
112.51 (5), 52.14 (14), 44.44 (10), 39.33 (11), 28.70 (15). 
MS ESI m/z (rel. %): 547 ([2M + Na]
+
), 285 ([M+Na]
+
), 263 ([M+H]
+
). 
 
MS EI m/z (rel. %): 262 (100, M
+
), 162 (25), 135 (88), 128 (12), 72 (41), 58 (26). 
HR-MS Found 262.1548 calcd. for C12H18N6O 262.1542. 
 
Compound not known in literature. 
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Spectrum 37. 
1
H NMR (MeOH-d4, 600 MHz) of 3-(6-amino-7H-purin-7-yl)-N-(tert-butyl)propanamide(44b). 
 
Spectrum 38. 
13
C NMR (MeOH-d4, 150 MHz) of 3-(6-amino-7H-purin-7-yl)-N-(tert-butyl)propanamide(44b). 
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Synthesis of 9-methoxy-9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-gh]purinium 
2,2,2-trifluoroacetate (18) 
 
tert-Butyl 6-(ditert-butoxycarbonylamino)-7-(3-oxobutyl)-8,9-dihydropurine-9-carboxylate (16) 
(1.012 g, 1.995 mmol) was dissolved in DCM (10 mL), molecular sieves 3Å (5 g) was added. 
Trifluoroacetic acid (2 mL) was added dropwise through the septum over a period of 3 minutes 
under an atmosphere of argon and the reaction mixture was stirred for 1 hour. The volatiles were 
removed in vacuo and the crude oil was dissolved in THF (10 mL) and DCM (10 mL). 
Manganese(IV) oxide (347 mg, 3.99 mmol) was added under an atmosphere of argon. The 
reaction was stirred for 2 hours before the mixture was filtered through a pad of celite, 
concentrated to a yellow oil and purified by flash column chromatography (silica gel, 
DCM:MeOH – 91:9) affording an off-white hygroscopic powder. 
Yield 556 mg (calc. 83 %
†
) 
1
H NMR (MeOH-d4, 500 MHz): δ 8.31 (s, 1H, 2), 8.29 (s, 1H, 8), 4.67 (td, J = 3.3 Hz, 13.0 Hz, 
1H, 10), 4.39 (dt, J = 3.3 Hz, 13.0 Hz, 1H, 10), 3.27 (s, 3H, 14), 2.55 (m, 2H, 11), 1.66 (s, 3H, 
13). 
13
C NMR (MeOH-d4, 125 MHz): δ 159.52 (4), 153.66 (2), 152.16 (6), 146.18 (8), 113.80 (5), 
85.29 (12), 56.74 (14), 43.31 (10), 40.83 (11), 26.07 (13). 
MS ESI m/z (rel. %): 461 ([2M + Na]
+
), 220 ([M + H]
+
). 
HR-MS Found 220.1196 calcd. for C10H14N5O 220.1193. 
M.p. Deliquescent. 
Compound not known in literature.  
                                                 
†
 Calculated by subtracting the amount of methanol present measured by 
1
H NMR from the weight of the isolated 
material. 
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Spectrum 39. 
1
H NMR (MeOH-d4, 500 MHz) of 9-methoxy-9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-
gh]purinium 2,2,2-trifluoroacetate (18). 
 
Spectrum 40. 
13
C NMR (MeOH-d4, 150 MHz) of 9-methoxy-9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-
gh]purinium 2,2,2-trifluoroacetate (18). 
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Synthesis of 9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-gh]purine (23)
 
9-Methoxy-9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-gh]purinium trifluoroacetate (18) 
(93 mg, 0.28 mmol) was dissolved in ethanol (10 mL), NaBH4 (42 mg, 1.1 mmol) was added and 
the reaction stirred for 24 h. The volatiles were evaporated in vacuo and the crude material was 
purified by flash column chromatography (DCM:MeOH:Et3N – 90:10:2) affording a colorless 
solid.  
Yield 49 mg (92 %). 
1
H NMR (MeOH-d4, 200 MHz): δ 8.25 (s, 1H, 2), 8.22 (s, 1H, 8), 4.60 (m, 1H, 10), 4.66 – 4.55 
(m, 1H, 10), 4.32 – 4.19 (m, 1H, 10), 3.88 – 3.73 (m, 2H, 12), 2.37 – 2.05 (m, 2H, 11). 1.46 (d, J 
= 6.6 Hz, 3H, 13). 
 
13
C NMR (MeOH-d4, 150 MHz): δ 154.58 (4), 153.80 (6), 149.85 (2), 146.93 (8), 112.61 (5), 
52.78 (12), 47.86 (10), 35.87 (11), 21.96 (13). 
 
MS EI m/z (rel. %): 190 (8), 189 (80, M
+
), 160 (4), 120 (19), 93 (3). 
 
HR-MS Found 189.1019 calcd. for C9H11N5 189.1014. 
M.p. >250 °C. 
Compound not known in literature.  
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Spectrum 41. 
1
H NMR (MeOH-d4, 200 MHz) of 9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-gh]purine (23). 
 
Spectrum 42. 
13
C NMR (MeOH-d4, 150 MHz) of 9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-gh]purine (23). 
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Synthesis of tert-butyl 6-iodo-7,8-dihydropurine-9-carboxylate (35) 
 
tert-Butyl 6-iodopurine-9-carboxylate (27) (862  mg, 2.49 mmol) was dissolved in MeOH (50 
mL). Sodium borohydride (475 mg, 12.6 mmol) was added and the mixture was stirred for 20 
minutes before water (20 mL) was added. The mixture was concentrated in vacuo until a white 
precipitate was formed. DCM (15 mL) and sodium chloride (0.5 g) was added and the layers 
separated. The water-phase was extracted with DCM (3 x 10 mL). The combined organic layers 
were dried over MgSO4, filtered and evaporated in vacuo to afford a colorless solid. 
Yield 659 mg (76 %). 
1
H NMR (CDCl3, 200 MHz): δ 8.04 (s, 1H, 2), 5.31 (s, 2H, 8), 4.04 (br s, 1H, 7), 1.54 (s, 9H, 
12). 
 
13
C NMR (CDCl3, 150 MHz): δ 151.38 (4), 149.83 (2), 148.77 (10), 137.99 (5), 99.63 (6), 84.05 
(11), 63.43 (8), 28.26 (12). 
 
MS EI m/z (rel. %): 256 (7, M
+
), 183 (7), 158/156 (17/60), 157/155 (35/100), 119 (48), 92 (7), 67 
(6), 57 (70). 
HR-MS Found 256.0726 calcd. for C10H13ClN4O2 256.0727. 
M.p. >164 °C (dec.) (lit. >165 °C (dec.)).    
Compound known in literature.
69
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Spectrum 43. 
1
H NMR (CDCl3, 200 MHz) of tert-butyl 6-iodo-7,8-dihydropurine-9-carboxylate (35). 
 
Spectrum 44. 
13
C NMR (CDCl3, 100 MHz) of tert-butyl 6-iodo-7,8-dihydropurine-9-carboxylate (35). 
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Synthesis of tert-butyl 2,6-dichloro-7,8-dihydropurine-9-carboxylate (38) 
 
tert-butyl 2,6-dichloropurine-9-carboxylate (30) (101  mg, 0.349 mmol) was dissolved in MeOH 
(5 mL). Sodium borohydride (27 mg, 0.71 mmol) was quickly and the mixture was stirred for 20 
minutes before water (5 mL) was added. The mixture was concentrated in vacuo until a white 
precipitate was formed. DCM (5 mL) and sodium chloride was added to the suspension. The 
layers were separated and the water-phase extracted with DCM (3 x 5 mL). The combined 
organic layers were dried over MgSO4, filtered and evaporated in vacuo to afford a colorless 
solid. 
Yield 76 mg (75 %). 
1
H NMR (CDCl3, 200 MHz): δ 5.37 (s, 2H, 8), 4.48 (br s, 1H, 7), 1.52 (s, 9H, 12). 
 
13
C NMR (CDCl3, 150 MHz): δ 156.20, 149.14, 148.17, 134.10, 130.24, 84.59, 77.16, 65.49, 
28.19. 
 
MS EI m/z (rel. %): 290 (3, M
+
), 190 (100). 
HR-MS Found 290.0330 calcd. for C10H12Cl2N4O2 290.0337. 
M.p.: >165 °C (dec.) 
Compound known in literature.
69
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Spectrum 45. 
1
H NMR (CDCl3, 200 MHz) of tert-butyl 2,6-dichloro-7,8-dihydropurine-9-carboxylate (38). 
 
Spectrum 46. 
13
C NMR (CDCl3, 100 MHz) of tert-butyl 2,6-dichloro-7,8-dihydropurine-9-carboxylate (38). 
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Synthesis of 6-methoxy-9-(tetrahydro-2H-pyran-2-yl)purine (42) 
 
6-Chloro-9-(tetrahydro-2H-pyran-2-yl)purine (33) (52 mg, 0.22 mmol) was dissolved in 
methanol (5 mL) and heated to reflux. NaBH4 (16 mg, 0.42 mmol) was added and the reaction 
was stirred for 40 min. The flask was cooled, volatiles removed in vacuo and the crude product 
purified was by flash column chromatography (DCM:MeOH – 97:3) affording a grey solid.  
Yield 12 mg (23 %). 
1
H NMR (MeOH-d4, 600 MHz): δ 8.53 (s, 1H, 2), 8.12 (s, 1H, 8), 5.75 – 5.73 (m, 1H, 10), 4.17 
(s, 3H, 150), 4.16 – 4.14 (m, 1H, 14), 3.78 – 3.74 (m, 1H, 14), 2.12 – 2.01 (m, 3H, 11/12), 1.80 –  
1.69 (m, 2H, 12/13), 1.67 – 1.62 (m, 1H, 13). 
 
13
C NMR (MeOH-d4, 150 MHz): δ 161.23 (6), 152.35 (2), 151.35 (4), 140.08 (8), 121.56 (5), 
82.27 (10), 68.96 (14), 54.39 (15), 31.95 (11), 25.01 (13), 22.95 (12). 
 
MS EI m/z (rel. %): 234 (27, M
+
), 206 (15), 152 (7), 151 (100), 149 (14), 121 (10), 120 (19), 93 
(12), 85 (62), 84 (33), 67 (15).   
HR-MS Found 240.0771 calcd. for C10H13ClN4O 240.0778. 
M.p. >250 °C. 
Compound not known in literature.  
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Spectrum 47. 
1
H NMR (CDCl3, 600 MHz) of 6-methoxy-9-(tetrahydro-2H-pyran-2-yl)purine (42). 
 
Spectrum 48. 
13
C NMR APT (CDCl3, 150 MHz) of 6-methoxy-9-(tetrahydro-2H-pyran-2-yl)purine (42). 
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Synthesis of 6-chloro-9-(((triisopropylsilyl)oxy)methyl)purine (32a) 
 
6-Chloropurine (296 mg, 1.92 mmol) was suspended in DCM (6 mL) and triethylamine (295 µL, 
2.12 mmol) was added. (Triisopropylsiloxy)methyl chloride (490 µL, 2.11 mmol) was added 
under an atmosphere of argon. The mixture was stirred for 30 minutes and the volatiles were 
removed in vacuo. The crude product was purified by flash column chromatography 
(hexanes:ethyl acetate – 7:3 to 3:7 gradient) affording a yellow solid.  
Yield 332 mg (51 %). 
1
H NMR (CDCl3, 600 MHz): δ 8.74 (s, 1H, 2), 8.30 (s, 1H, 8), 5.89 (s, 2H, 10), 1.17 (sept, J = 
7.5 Hz, 3H, 11), 1.03 (d, J = 7.5 Hz, 18H, 12). 
 
13
C NMR (CDCl3, 150 MHz): δ 152.33 (2), 151.31 (4), 151.24 (6), 144.79 (8), 131.63 (5), 68.34 
(10), 17.88 (12), 11.98 (11). 
 
MS EI m/z (rel. %): 300 (6), 299 (37), 298 (19), 297 (100), 211 (7).   
 
MS ESI m/z (rel. %): 341 ([M+H]
+
). 
 
HR-MS Found 341.1555 calcd. for C15H26ClN4OSi 341.1559. 
 
M.p. 71 – 72 °C. 
 
Compound not known in literature.  
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Spectrum 49. 
1
H NMR (CDCl3, 600 MHz) of 6-chloro-9-(((triisopropylsilyl)oxy)methyl)purine (32a). 
 
Spectrum 50. 
1
H NMR (CDCl3, 150 MHz) of 6-chloro-9-(((triisopropylsilyl)oxy)methyl)purine (32a). 
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Synthesis of 6-chloro-7-(((triisopropylsilyl)oxy)methyl)purine (32b) 
 
 
6-Chloropurine (296 mg, 1.92 mmol) was suspended in DCM (6 mL) and triethylamine (295 µL, 
2.12 mmol) was added. (Triisopropylsiloxy)methyl chloride (490 µL, 2.11 mmol) was added 
under an atmosphere of argon. The mixture was stirred for 30 minutes and the volatiles were 
removed in vacuo. The crude product was purified by flash column chromatography 
(hexanes:ethyl acetate – 7:3 to 3:7 gradient) affording a yellow solid.  
Yield 235 mg (36 %). 
1
H NMR (CDCl3, 600 MHz): δ 8.88 (s, 1H, 2), 8.39 (s, 1H, 8), 6.03 (s, 2H, 10), 1.17 (sept, J = 
7.5 Hz, 3H, 11), 1.04 (d, J = 7.5 Hz, 18H, 12). 
 
13
C NMR (CDCl3, 150 MHz): δ 162.47 (4), 152.89 (2), 148.29 (8), 143.40 (6), 122.07 (5), 71.20 
(10), 17.90 (12), 12.03 (11). 
 
MS EI m/z (rel. %): 300 (8), 299 (33), 298 (22), 297 (100), 211 (11).   
 
M.p. 88 – 89 °C. 
 
Compound not known in literature.  
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Spectrum 51. 
1
H NMR (CDCl3, 600 MHz) of 6-chloro-7-(((triisopropylsilyl)oxy)methyl)purine (32b). 
 
Spectrum 52. 
13
C NMR (CDCl3, 150 MHz) of 6-chloro-7-(((triisopropylsilyl)oxy)methyl)purine (32b). 
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Synthesis of 6-methoxypurine (24) 
 
Sodium (450 mg, 19.6 mmol) was added to methanol (8 mL) and allowed to react and dissolve. 
This solution was added to 6-chloropurine (300 mg, 1.94 mmol) and the suspension heated to 65 
°C on an oil bath. The reaction was stirred for 24 hours before being cooled and acetic acid (0.5 
mL) was added. The volatiles were removed in vacuo and the crude product purified by flash 
column chromatography (DCM:MeOH – 9:1) affording a colorless solid.  
Yield 247 mg (85 %). 
 
1
H NMR (DMSO-d6, 200 MHz): δ 13.38 (br s, 1H, 9), 8.50 (s, 1H, 2), 8.37 (s, 1H, 8), 4.09 (s, 
3H, 10, 2.50. 
 
13
C NMR (CDCl3, 150 MHz): δ 154.72 (4), 149.50 (2), 148.49 (10), 134.13 (6), 131.00 (5), 
84.20 (11), 64.68 (8), 28.27 (12). 
 
MS EI m/z (rel. %): 151 (8), 150 (100, M
+
), 149 (60), 121 (36), 120 (38), 93 (47), 66 (21), 53 (9). 
 
HR-MS Found 150.0547 calcd. for C6H6N4O 150.0542. 
 
M.p. 190 – 191 °C (lit. 195 – 196 °C98).  
 
Compound known in literature.
98,99
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Spectrum 53. 
1
H NMR (DMSO-d6, 200 MHz) of 6-methoxypurine (24). 
 
Spectrum 54. 
13
C NMR (DMSO-d6, 100 MHz) of 6-methoxypurine (24). 
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Synthesis of 6-(piperidin-1-yl)purine (25) 
 
6-Chloropurine (344 mg, 2.23 mmol) was dissolved in 1-butanol (5 mL) and piperidine (1.10 mL, 
11.1 mmol) was added. The solution was heated to 100 °C on an oil bath and stirred for 18 hours. 
The mixture was cooled and the volatiles were removed in vacuo. The crude product was purified 
by flash column chromatography (DCM:MeOH – 95:5) affording a yellow solid. 
Yield 432 mg (95 %). 
1
H NMR (DMSO-d6, 400 MHz): δ 12.94 (bs, 1H, 9), 8.17 (s, 1H, 2), 8.07 (s, 1H, 8), 4.19 (br s, 
4H, 10), 1.71 – 1.65 (m, 2H, 12), 1.60 – 1.54 (m, 4H, 11). 
 
13
C NMR (DMSO-d6, 100 MHz): δ 153.10 (6), 151.81 (2), 151.29 (4), 137.68 (8), 118.65 (5), 
45.57 (10), 25.65 (11), 24.29 (12). 
 
MS EI m/z (rel. %): 204 (11), 203 (100, M
+
), 202 (20), 188 (15), 175 (12), 174 (83), 160 (33), 
148 (34), 147 (31), 135 (24), 120 (30), 93 (20), 84 (14). 
 
HR-MS Found 203.1169 calcd. for C10H13N5 203.1171. 
 
M.p. 277 – 278 °C (lit. 277 – 278 °C104). 
 
Compound known in literature.
104
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Spectrum 55. 
1
H NMR (DMSO-d6, 400 MHz) of 6-(piperidin-1-yl)purine (25). 
 
 
Spectrum 56. 
13
C NMR (DMSO-d6, 100 MHz) of 6-(piperidin-1-yl)purine (25). 
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6. APPENDIX 
 
Spectrum 57. COSY (400 MHz, DMSO-d6) of 3-((5-amino-6-chloropyrimidin-4-yl)amino)propan-1-ol (2). 
 
Spectrum 58. HMBC (400 MHz, DMSO-d6) of 3-((5-amino-6-chloropyrimidin-4-yl)amino)propan-1-ol (2). 
116 
 
 
Spectrum 59. COSY (DMSO-d6, 500 MHz) of 8-chloro-3,4-dihydropyrimido[1,6-a]pyrimidin-9-amine 
hydrochloride (7). 
 
Spectrum 60. HSQC (DMSO-d6, 500 MHz) of 8-chloro-3,4-dihydropyrimido[1,6-a]pyrimidin-9-amine 
hydrochloride (7). 
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Spectrum 61. HMBC (DMSO-d6, 500 MHz) of 8-chloro-3,4-dihydropyrimido[1,6-a]pyrimidin-9-amine 
hydrochloride (7). 
 
Spectrum 62 HSQC (DMSO-d6, 400 MHz) of 3-((5-amino-6-chloropyrimidin-4-yl)(methyl)amino)propan-1-ol (10). 
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Spectrum 63 HMBC (DMSO-d6, 400 MHz) of 3-((5-amino-6-chloropyrimidin-4-yl)(methyl)amino)propan-1-ol 
(10). 
 
Spectrum 64 COSY (DMSO-d6, 400 MHz) of 9-amino-8-chloro-1-methyl-1,2,3,4-tetrahydropyrimido[1,6-
a]pyrimidinium chloride (11). 
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Spectrum 65 HSQC (DMSO-d6, 400 MHz) of 9-amino-8-chloro-1-methyl-1,2,3,4-tetrahydropyrimido[1,6-
a]pyrimidinium chloride (11). 
 
Spectrum 66 HMBC (DMSO-d6, 400 MHz) of 9-amino-8-chloro-1-methyl-1,2,3,4-tetrahydropyrimido[1,6-
a]pyrimidinium chloride (11). 
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Spectrum 67 COSY (CDCl3, 600 MHz) of tritert-butyl 9,10,10-adenineetricarboxylate (14). 
 
Spectrum 68 HSQC (CDCl3, 600 MHz) of tritert-butyl 9,10,10-adenineetricarboxylate (14). 
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Spectrum 69 HSQC (CDCl3, 600 MHz) of tritert-butyl 9,10,10-adenineetricarboxylate (14). 
 
Spectrum 70 COSY (CDCl3, 600 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-
carboxylate (15). 
122 
 
 
Spectrum 71 HSQC (CDCl3, 600 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-
carboxylate (15). 
 
Spectrum 72 HMBC (CDCl3, 600 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-
carboxylate (15). 
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Spectrum 73 COSY (CDCl3, 600 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-7-(3-oxobutyl)-8,9-
dihydropurine-9-carboxylate (16). 
 
Spectrum 74 HSQC (CDCl3, 600 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-7-(3-oxobutyl)-8,9-
dihydropurine-9-carboxylate (16). 
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Spectrum 75 HSQC (CDCl3, 600 MHz) of tert-butyl 6-(ditert-butoxycarbonylamino)-7-(3-oxobutyl)-8,9-
dihydropurine-9-carboxylate (16). 
 
Spectrum 76 HSQC (CDCl3, 400 MHz) of tert-butyl 7-(2-cyanoethyl)-6-(ditert-butoxycarbonylamino)-8,9-
dihydropurine-9-carboxylate  (43). 
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Spectrum 77 HMBC (CDCl3, 400 MHz) of tert-butyl 7-(2-cyanoethyl)-6-(ditert-butoxycarbonylamino)-8,9-
dihydropurine-9-carboxylate  (43). 
 
Spectrum 78 COSY (CDCl3, 600 MHz) of tert-butyl 6-chloropurine-9-carboxylate (26). 
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Spectrum 79 HSQC (CDCl3, 600 MHz) of tert-butyl 6-chloropurine-9-carboxylate (26). 
 
Spectrum 80 HMBC (CDCl3, 600 MHz) of tert-butyl 6-chloropurine-9-carboxylate (26). 
 
127 
 
 
Spectrum 81 COSY (CDCl3, 600 MHz) of tert-butyl 6-iodopurine-9-carboxylate (27). 
 
Spectrum 82 HSQC (CDCl3, 600 MHz) of tert-butyl 6-iodopurine-9-carboxylate (27). 
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Spectrum 83 HSQC (CDCl3, 600 MHz) of tert-butyl 6-iodopurine-9-carboxylate (27). 
 
Spectrum 84 NMR (CDCl3, 500 MHz) of tert-butyl 6-methoxypurine-9-carboxylate( 28).  
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Spectrum 85 HSQC (CDCl3, 400 MHz) of tert-butyl 2,6-dichloropurine-9-carboxylate (30). 
 
Spectrum 86 HMBC (CDCl3, 400 MHz) of tert-butyl 2,6-dichloropurine-9-carboxylate (30). 
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Spectrum 87 COSY (CDCl3, 400 MHz) of tert-butyl purine-9-carboxylate (31a) and tert-butyl purine-7-carboxylate 
(31b). 
 
Spectrum 88 HSQC (CDCl3, 400 MHz) of tert-butyl purine-9-carboxylate (31a) and tert-butyl purine-7-carboxylate 
(31b). 
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Spectrum 89  HMBC (CDCl3, 400 MHz) of tert-butyl purine-9-carboxylate (31a) and tert-butyl purine-7-
carboxylate (31b). 
 
Spectrum 90  COSY (CDCl3, 400 MHz) of tert-butyl 6-chloro-7,8-dihydropurine-9-carboxylate (34). 
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Spectrum 91 HSQC (CDCl3, 400 MHz) of tert-butyl 6-chloro-7,8-dihydropurine-9-carboxylate (34). 
 
Spectrum 92 HMBC (CDCl3, 400 MHz) of tert-butyl 6-chloro-7,8-dihydropurine-9-carboxylate (34). 
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Spectrum 93 HSQC (CDCl3, 400 MHz) of tert-butyl 7-benzyl-6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-9-
carboxylate (19). 
 
Spectrum 94 HMBC (CDCl3, 400 MHz) of tert-butyl 7-benzyl-6-(ditert-butoxycarbonylamino)-8,9-dihydropurine-
9-carboxylate (19). 
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Spectrum 95 COSY (DMSO-d6, 600 MHz) of 7-benzylpurin-6-amine (21). 
 
Spectrum 96 HSQC (DMSO-d6, 600 MHz) of 7-benzylpurin-6-amine (21). 
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Spectrum 97 HMBC (DMSO-d6, 600 MHz) of 7-benzylpurin-6-amine (21). 
 
Spectrum 98 COSY (DMSO-d6, 400 MHz) of 3-(6-aminopurin-7-yl)propanenitrile (44a). 
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Spectrum 99 HSQC (DMSO-d6, 400 MHz) of 3-(6-aminopurin-7-yl)propanenitrile (44a). 
 
Spectrum 100 HMBC (DMSO-d6, 400 MHz) of 3-(6-aminopurin-7-yl)propanenitrile (44a). 
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Spectrum 101 COSY (MeOH-d4, 600 MHz) of 3-(6-amino-7H-purin-7-yl)-N-(tert-butyl)propanamide(44b). 
 
Spectrum 102 HSQC (MeOH-d4, 600 MHz) of 3-(6-amino-7H-purin-7-yl)-N-(tert-butyl)propanamide(44b). 
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Spectrum 103 HMBC (MeOH-d4, 600 MHz) of 3-(6-amino-7H-purin-7-yl)-N-(tert-butyl)propanamide(44b). 
 
Spectrum 104 COSY (MeOH-d4, 500 MHz) of 9-methoxy-9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-
gh]purinium 2,2,2-trifluoroacetate (18). 
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Spectrum 105 HSQC (MeOH-d4, 500 MHz) of 9-methoxy-9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-
gh]purinium 2,2,2-trifluoroacetate (18). 
 
Spectrum 106 HMBC (MeOH-d4, 500 MHz) of 9-methoxy-9-methyl-7,8,9,10-tetrahydro-[1,4]diazepino[1,2,3-
gh]purinium 2,2,2-trifluoroacetate (18). 
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Spectrum 107 HSQC (CDCl3, 400 MHz) of tert-butyl 6-iodo-7,8-dihydropurine-9-carboxylate (35). 
 
Spectrum 108 HSQC (CDCl3, 400 MHz) of tert-butyl 6-iodo-7,8-dihydropurine-9-carboxylate (35). 
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Spectrum 109 HSQC (CDCl3, 400 MHz) of tert-butyl 2,6-dichloro-7,8-dihydropurine-9-carboxylate (38). 
 
Spectrum 110 HMBC (CDCl3, 400 MHz) of tert-butyl 2,6-dichloro-7,8-dihydropurine-9-carboxylate (38). 
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Spectrum 111 COSY (CDCl3, 600 MHz) of 6-methoxy-9-(tetrahydro-2H-pyran-2-yl)purine (42). 
 
Spectrum 112 HSQC (CDCl3, 600 MHz) of 6-methoxy-9-(tetrahydro-2H-pyran-2-yl)purine (42). 
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Spectrum 113 HMBC (CDCl3, 600 MHz) of 6-methoxy-9-(tetrahydro-2H-pyran-2-yl)purine (42). 
 
Spectrum 114 HMBC (CDCl3, 600 MHz) of 6-chloro-9-(((triisopropylsilyl)oxy)methyl)purine (32a). 
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Spectrum 115 HMBC (CDCl3, 600 MHz) of 6-chloro-9-(((triisopropylsilyl)oxy)methyl)purine (32b). 
 
Spectrum 116 HSQC (DMSO-d6, 400 MHz) of 6-(piperidin-1-yl)purine (25). 
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Spectrum 117 HSQC (DMSO-d6, 400 MHz) of 6-(piperidin-1-yl)purine (25). 
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